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ABSTRACT 
Andrew S. McDaniel 
 
THE ROLE OF PAK1 IN THE CELLULAR AND MOLECULAR COMPONENTS OF 
PLEXIFORM NEUROFIBROMAS 
 
Neurofibromatosis type I (NF1) is a common genetic disease that affects over 
200,000 patients in North America, Europe, and Japan.   Individuals with NF1 display a 
wide variety of  pathologies; importantly, 15-40% of NF1 patients are affected by 
plexiform neurofibromas.   Neurofibromas are complex tumors consisting of tumorgenic 
Schwann cells surrounded by endothelial cells, fibroblasts, and inflammatory mast cells. 
These peripheral nerve sheath tumors contribute significantly to the morbidity and 
mortality associated with NF1.   Currently, no medical therapies exist for treating 
neurofibromas.  Recent evidence indicates that the hematopoietic tumor 
microenvironment carries out a crucial function in the formation of plexiform 
neurofibromas.  Neurofibromatosis is the result of mutations at the NF1 locus, which 
encodes the GTPase activating protein neurofibromin.   Neurofibromin is a negative 
regulator of the proto-oncogene Ras.   Ras hyperactivation is the molecular basis of NF1 
associated phenotypes, and it has been demonstrated that restoration of Ras signaling to 
wild type levels can correct NF1 associated phenotypes in vitro and in vivo.   In keeping 
with the long term goal of detecting potential molecular targets for medical therapies to 
treat human plexiform neurofibromas, we have identified the kinase Pak1 as a possible 
downstream intermediary of Ras signaling in NF1 deficient cells.  Studies described here 
 v 
utilized murine genetic models to study the effects of genetic inactivation of Pak1 on 
molecular signaling and cellular functions related to neurofibromas.  We demonstrate that 
inactivation of Pak1 leads to correction of SCF mediated gain-in-function phenotypes 
seen in Nf1 haploinsufficient mast cells, in vivo and in vitro.   However, by using a 
conditional Nf1 knockout mouse that is a reliable model of plexiform neurofibroma 
formation, we shown that loss of Pak1 alone in the hematopoeitic compartement is not 
sufficient to prevent neurofibroma formation.  Additionally, we describe a key role for 
Pak1 in regulating PDGF and TGF-β mediated fibroblast functions, in vitro and in vivo.  
These studies provide insight into the causes of debilitating tumors related to a common 
genetic disease, and this research could potentially lead to the development of medical 
therapies for these tumors, increasing the  quality of life for tens of thousands of affected 
individuals each year. 
 
 
       D. Wade Clapp, M.D., Chair 
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INTRODUCTION 
 
In 1882, Fredrich von Recklinghausen reported on a 47-year-old male with 
“innumerable tumors” in the outer skin layer.  In this report, he remarked that these 
tumors were outgrowths of the “externally palpable peripheral nerve trunks”, and in 
doing so, described the characteristic lesion of the genetic cancer syndrome 
neurofibromatosis type 1 (NF1) 
1
.  Although reports of probable neurofibromatosis cases 
date back to the sixteenth century, and despite an initial review of the disease by Robert 
W. Smith in 1849 
2
; it was von Recklinghausen’s seminal observation that the tumors 
afflicting the skin of patients with this disease are derived from neural tissue that 
instigated significant clinical interest and linked his name to this disease.  Today, more 
than 250,000 people in the United States, Europe and Japan alone are living with NF1; 
greater than the number of cystic fibrosis, hereditary muscular dystrophy, Huntington’s 
disease, and Tay-Sach’s disease patients combined. 
 
Disease manifestations of Neurofibromatosis type 1 
 
 NF1 is the most common autosomal dominant genetic disease in humans, with an 
overall incidence of about 1 in 3500 
3
.  Together with Neurofibromatosis type 2, Von-
Hipple Lindau syndrome, tuberous sclerosis, and Sturge-Weber syndrome, NF1 is 
historically classified as a phakomatosis (neurocutaneous syndrome), due to the presence 
of both dermatologic and neurologic sequelae.  Individuals affected with NF1 have a 
propensity to develop an array of non-malignant and malignant clinical complications 
4
.  
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Skeletal abnormalities, café-au-lait macules, learning disabilities, and other non-
malignant complications of NF1 have significant morbidity for affected patients.  In 
addition, children with NF1 are at an increased risk to develop myeloid disorders, 
especially juvenile myelomonocytic leukemia (JMML) after NF1 loss of heterozygosity 
in hematopoietic stem and progenitor cells 
5,6
.  
 While the development of other neoplasms such as malignant peripheral nerve 
sheath tumors (MPNSTs), pheochromocytomas and optic gliomas are also well described 
in NF1 patients; the most commonly found NF1 related tumor is the neurofibroma (>95% 
of all patients) 
7
.  These are complex tumors of the central and peripheral nervous system 
characterized by aggregations of Schwann cells, fibroblasts, and large deposits of 
extracellular matrix 
4
.  Additionally, these lesions are highly vascular with increased 
concentrations of pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) 
8
.  Furthermore, neurofibromas have a >50 
fold higher concentration of mast cells compared to adjacent non-affected areas of skin 
9
.    
Neurofibromas can be classified into two basic groups: dermal/subcutaneous or 
plexiform 
10
.  Dermal/subcutaneous neurofibromas are associated with morbidities such 
as pain, cosmetic problems, and pruritus (that is unresponsive to antihistamine therapy) 
11
.  The number of dermal/subcutaneous neurofibromas varies (from <20 to >2000 per 
individual) from patient to patient as well as between families 
12,13
.  Dermal/subcutaneous 
neurofibromas often appear during the onset of puberty and are known to increase in 
number and size with age and/or pregnancy 
14
.  However, plexiform neurofibromas, 
which affect 15-40% of NF1 patients, are generally congenital 
15
.  These tumors have 
significant impact in the quality of life of NF1 patients, and plexiform neurofibromas 
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have the potential to inflict severe morbidity upon NF1 patients, including severe 
disfigurement, life-threatening organ dysfunction, and premature death 
12
.  While 
dermal/subcutaneous neurofibromas are usually benign, plexiform neurofibromas are 
capable of malignant transformation to MPNSTs.  Plexiform neurofibromas carry up to a 
10% lifetime risk of malignant transformation, usually accompanied by widespread 
metastasis 
16,17
.  
 At present, therapies for neurofibromas are lacking at best.  For 
dermal/subcutaneous neurofibromas surgery is the only treatment option, and this is often 
impractical or impossible due to the sheer number or complexity of the tumors.  
Furthermore, surgical resection of dermal/subcutaneous neurofibromas is often followed 
by regrowth of the tumor and/or hypertrophic scarring 
11
.  Plexiform neurofibromas, due 
to their location, mass, and diffuse morphology, create significant challenges for effective 
treatment.  Many plexiform neurofibromas are not candidates for surgical resection due 
to the risk of hemorrhage owing to the highly vascular nature of these tumors (especially 
facial plexiforms) as well as encroachment into neighboring structures.  Radiotherapy of 
benign plexiform neurofibromas is contraindicated due to the risk of instigating 
malignant change 
11
.  Furthermore, no effective medical therapies for neurofibromas 
exist.  Considering the significant clinical complications caused by neurofibromas in 
patients, the need to identify molecular targets for pharmacologic therapies is pressing.  
 
 
 
 
 4 
Genetic basis of neurofibromatosis type 1 
 
Work using linkage analysis identified the gene responsible for NF1 to reside on 
chromosome 17 
18
.  Positional cloning led to the discovery of the NF1 locus at 17q11.2 
19-
21
.  The NF1 locus is composed of 60 exons that span over 300kb of genomic DNA and 
encodes a protein, neurofibromin, which contains 2818 amino acids 
22-24
.  Neurofibromin 
is ubiquitously expressed in all tissues; however, neurons, Schwann cells, astrocytes, 
oligodendroctyes, and leukocytes are noted for their exceptionally high expression of 
NF1 
19,25
.  Approximately 50% of NF1 diagnoses are the result of new mutations 
26
; 
therefore it is not surprising that a variety of NF1 mutations have been described, 
including missense replacements and truncations along the length of the entire gene 
27
.  It 
is interesting to note that to date, no correlation between specific mutations and clinical 
presentation or severity has been reported 
27
.    
 
Murine models of Neurofibromatosis type 1 
  
 Initial attempts to model neurofibromatosis in mice used homologous 
recombination techniques to target Nf1, the murine homolog of NF1, for disruption 
28
.  
Attempts to generate Nf1
-/-
 mice were not successful, as these embryos died between days 
12 and 14 post-coitus due abnormalities of cardiac development, specifically located in 
the outlet vessels of the right ventricle 
28
.  Furthermore, while Nf1
+/-
 mice were generated 
without cardiac malformations, a proportion of Nf1
+/-
 mice (~10%) did develop a 
myeloproliferative disorder reminiscent of JMML during the second year of life, 
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complete with leukemic cells that display loss of heterozygosity at the intact Nf1 allele 
28
 
and in vitro hypersensitivity to GM-CSF 
29
, similar to human JMML samples.  
Importantly, Nf1
+/-
 mice do not develop either dermal/subcutaneous or plexiform 
neurofibromas.  However, since NF1 patients are obligate heterozygotes, these animals 
have proven useful for studying the basic cellular biology of cells found in and near 
neurofibromas. 
 A second generation of murine neurofibromatosis type 1 models was initiated 
with the development of a conditionally deleted Nf1 mouse, using a Cre-Lox system 
30
.  
By breeding the Nf1
flox/flox
 mice with mice that expressed Cre driven by various lineage 
selective promoters, adult mice could be generated with specific organ systems that 
totally lacked neurofibromin.  Creating a conditional knockout of Nf1 that caused 
deletions in Schwann cells (by means of the Krox20 promoter driving Cre expression) 
yielded interesting results.  Although tumor samples from patients have demonstrated that 
Schwann cells harbor the somatic NF1 mutation 
31
, mice that contained Nf1 null Schwann 
cells (Krox20Cre:Nf1
flox/flox
) did not develop neurofibromas 
30
.  However, despite the fact 
that Krox20Cre;Nf1
flox/flox
 mice are functionally wild type, Krox20Cre;Nf1
flox/flox
 mice that 
were backcrossed with Nf1
+/-
 mice to generate one conditionally deleted allele and one 
traditionally disrupted allele (Krox20Cre;Nf1
flox/-
) developed multiple neurofibromas 
30
.  
These experiments demonstrated that nullizygosity of Nf1 in tumorigenic 
Schwann cells is necessary, but not sufficient for plexiform neurofibroma formation.  
Critically, haploinsufficiency of Nf1 in at least a subset of lineages within the tumor 
microenvironment is required to promote neurofibroma development.  The results 
generated from the Krox20Cre NF1 murine model have laid a foundation for the 
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development of rationally designed therapeutics that target the cells of the 
microenvironment rather than the tumorigenic cells alone.  
 
Role of mast cells in neurofibroma formation 
 
 Virchow first hypothesized that cancer was the result of an overactive 
inflammatory response in 1863; indeed, recent studies in multiple murine models have 
supported this hypothesis and implicated that inflammatory cells are essential for the 
progression to malignancy 
32
.  Chronic inflammation is well known to contribute directly 
to the formation of breast 
33
, hepatic 
34
, dermal 
35
, ovarian 
36
, prostate 
37
, and many other 
carcinomas.  Patients with chronic inflammatory diseases such as Crohn’s disease and 
ulcerative colitis have increased risks for developing colorectal carcinoma 
38
.  Further 
evidence underscoring the importance of inflammation on colon cancer development 
were studies demonstrating patients who were treated long term with non steroidal anti 
inflammatory drugs (NSAIDs) had nearly a 50% reduction in their overall risk of 
developing large bowel adenocarcinoma 
39
.   
Besides mediating innate immune responses and allergic hypersensitivity, there is 
an emerging understanding that inflammatory mast cells in the tumor microenvironment 
have relevance in the promotion of neoplastic development as well.  Described 
relationships between mast cells and tumors date back over 100 years 
40
; Mast cells in 
particular are critical for the transformation to malignancy in a squamous epithelial 
cancer murine model, by releasing matrix metalloproteinases such as tryptase and 
activating progelatinase B to activate the angiogenic switch 
41
.  Since mast cells are the 
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predominant inflammatory cell found in the neurofibroma microenvironment and are 
found at such high density at these sites 
9
, we have been particularly interested in 
understanding the potential role these cells play in neurofibroma pathophysiology.       
One notable observation drawn from the Krox20Cre;Nf1
flox/-
 mouse model is the 
appearance of mast cells in peripheral nerves well in advance of tumor development 
30
.  
Our laboratory has generated data identifying potential mechanisms that regulate the 
unique association of mast cells with neurofibromas, centered on the c-Kit/stem cell 
factor (SCF) signaling axis.  SCF, a glycoprotein also known as Steel factor, mast cell 
growth factor or Kit ligand, is the ligand of the receptor tyrosine kinase (RTK) c-kit 
42,43
.  
SCF exists in both soluble and membrane-bound forms 
44
.  SCF is a cytokine that induces 
pleotropic effects; resulting in the growth and development of hematopoietic stem      
cells 
45
, germ cells 
46
, and melanocytes 
47
.  Importantly, SCF is a potent mitogenic factor 
for mast cells 
48-50
.  SCF also stimulates mast cell chemotaxis 
51,52
 and survival 
53,54
.  
Upon stimulation with SCF or cross-linking of IgE molecules on the cell surface, mast 
cells release numerous inflammatory byproducts 
55,56
.  These include VEGF, which 
stimulates angiogenesis and Schwann cell proliferation 
57
, transforming growth factor 
beta (TGF-β) 58, which is a known growth factor for fibroblasts, as well as many reactive 
oxygen species and proteases.  Therefore, mast cells have the ability to stimulate the 
growth of cells that compose the neurofibroma as well as remodel the extracellular 
matrix.   
We have demonstrated that Nf1 haploinsufficient mast cells have increased 
proliferation, survival, migration, and degranulation in vitro and in vivo 
59-61
.  These 
findings identify that loss of one copy of Nf1 has functional consequences in mast cells.  
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We have shown that Nf1+/- mast cells preferentially migrate toward SCF released from 
Nf1-/- Schwann cells compared to wild type mast cells 
62
.  This Schwann cell/mast cell 
interaction resulting from the hypersecretion of SCF is thought to be an inciting factor in 
the early development of neurofibromas 
63
.   
   Studies by Dr. Feng-Chun Yang have revealed the importance of contributions 
from bone marrow derived cells to neurofibroma development in vivo.  Nf1
+/-
 bone 
marrow was transplanted into Krox20Cre;Nf1
flox/flox
 mice (which normally do not develop 
tumors).  By one year post-transplant, 100% of the Krox20Cre;Nf1
flox/flox
 mice 
reconstituted with Nf1
+/-
 marrow had neurofibromas 
64
.  As a complementary experiment, 
wild type marrow was transferred into Krox20Cre;Nf1
flox/-
 mice (which spontaneously 
develop tumors).  Interestingly, by one year post transplant, these Krox20Cre;Nf1
flox/-
 
mice did not generate neurofibromas 
64
.  These experiments show that Nf1 
haploinsufficiency in the hematopoietic portion of the tumor microenvironment is 
required to induce Schwann cells into forming neurofibromas.  
Additional experiments utilized Krox20Cre;Nf1
flox/flox
 mice transplanted with 
Nf1
+/-
;W
41
W
41
 marrow.  The W
41
 mutation in the c-kit receptor kinase domain leads to 
mice with a mottled coat color, normal bone marrow cellularity, mild but persistent 
anemia, and markedly decreased numbers of mast cells and their progenitors 
65
.  
Krox20Cre;Nf1
flox/flox
 mice that were recipients of Nf1
+/-
;W
41
W
41
 marrow did not develop 
plexiform neurofibromas 
64
, implying that the identity of the active component of the 
tumor-promoting hematopoietic compartment to be a c-Kit dependent cell type, such as 
mast cells.  Given the results from in vitro studies on mast cell activity and our data using 
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the Krox20Cre conditional knockout of Nf1, we hypothesize that haploinsufficiency at 
Nf1 in mast cells specifically is required for the evolution to neoplasia in vivo. 
 
Fibroblasts contribute to neurofibroma pathology 
 
Fibrosis often develops in chronic inflammatory conditions that involve large-
scale mast cell activation.  In pathologically fibrotic conditions such as scleroderma, post-
operative peritoneal adhesions, and radiation induced lung fibrosis, high densities of mast 
cells are observed 
66
.  Mast cells can provide growth factors that stimulate this fibroblast 
growth and invasion, such as TGF-β and PDGF 38,58.   
 Fibroblasts are also an important component of neurofibromas, and are known to 
secrete large amounts of extracellular matrix (ECM) at the tumor site 
67
.  Indeed, up to 
50% of the dry weight of neurofibromas is composed of ECM, mainly collagen 
68
.  The 
invasion, proliferation, and the extracellular matrix released by fibroblasts in developing 
tumors, besides adding bulk and mass to neurofibromas, are critical for providing an 
cellular and protein foundation for angiogenesis and Schwann cell invasion 
69
.  
Additionally, fibroblasts that are disrupted at Nf1 have a reduced capability to form 
perineurial sheaths around Schwann cells, allowing increased access for mast cells and 
serum growth factors to Schwann cells 
70
. 
 Furthermore, we have recently demonstrated that Nf1+/- mast cells secrete 
increased amounts of TGF-β, and that this leads to Ras dependent gains of function in 
proliferation, migration, and ECM secretion by Nf1+/- fibroblasts 
71
.  This data provides 
a potential mechanism for the profound fibrosis seen histologically in neurofibroma 
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samples and again implicates the mast cell as an inducer, via paracrine factors, of cellular 
events important for neurofibroma formation. 
  
Ras hyperactivation: the molecular basis of NF1 
  
As a tumor suppressor, neurofibromin functions as a member of a molecular 
switchboard involved in transducing extracellular signals to the nucleus via Ras 
3
.  
Neurofibromin acts as an important negative regulator of this signaling network by acting 
as a GTPase activating protein (GAP) via its binding to active Ras and increasing GTP 
hydrolysis 
72
.  In hematopoietic cells, p120 GAP is also expressed, although the gene 
encoding this protein is not associated with cancer development 
73
.  The Ras-GAP related 
domain (GRD) responsible for GTPase inactivation is located between amino acids 1125-
1537 in NF1 
20
.  NF1 GRD is highly homologous with p120 GAP catalytic domain 
72
; 
however, reconstitution of Nf1 deficient cells with Nf1 GRD, but not p120 GRD, is 
sufficient to correct gain-in-function phenotypes, both in vitro and in vivo 
62,74,75
.  
Although neurofibromin has been described to regulate cAMP levels 
76
 and associate 
with microtubules 
77
; to date, Ras-GRD is the only domain within neurofibromin with an 
associated biological function that has an impact on disease 
10
.   
Ras coordinates the growth, differentiation, and survival of many cell types and 
its activation status is tightly regulated 
78
.  Upon ligand binding, numerous growth factor 
receptors (including c-Kit) recruit Ras to the plasma membrane and initiate the formation 
of an activation complex that includes the Grb2 adapter and guanine nucleotide exchange 
factor Sos, which loads GTP onto Ras.  Signal transduction from the Ras network 
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proceeds until GAP proteins are able to bind Ras and facilitate the hydrolysis of GTP to 
GDP.  Therefore loss or inactivation of Nf1 leads to a shift towards increased Ras-GTP 
vis-à-vis Ras-GDP, leading to hyperactivation of downstream signaling molecules 
79
.  
Hyperactivation of Ras at the molecular level is believed to be responsible for NF1 
related pathologies ranging from JMML 
80
, pilocytic astrocytomas 
81
, optic glioma 
82
, 
learning disabilities 
83
, and neurofibromas 
84
.  
 
Signaling pathways disrupted in the absence of neurofibromin 
 
Ras activation by in response to growth factor stimulation leads to the recruitment 
and activity of Raf-1 serine/threonine kinase 
85
.  Raf-1, in turn activates the MAPKK 
Mek1/2 
86
 and subsequently p42/p44 MAPK (Erks) 
87,88
.  This classical Ras/Raf/Mek/Erk 
cascade is well described as essential to numerous cells type for the proliferation and 
survival signals sent by growth factors such as interleukin-3 (IL-3), granulocyte-
macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF), and many 
others 
89-91
.  Many groups have found hyperactivation of the Ras/Raf/Mek/Erk pathway 
following growth factor stimulation in the context of neurofibromin deficiency, 
particularly in cellular lineages relevant to neurofibromas, including: Schwann cells 
92
, 
fibroblasts 
71
, endothelial cells 
93
, vascular smooth muscle cells 
94
, and mast cells 
59
.  
Additionally, Ras has been demonstrated to bind to the p110 catalytic subunit of 
Class I phosphatidylinositol 3-kinases (PI3-K), leading to increased lipid kinase     
activity 
95
.  Similar to Ras, PI3-K itself tranduces signals through a number of networks 
to regulate multiple cellular functions 
95
.  Some downstream effectors of PI3-K have been 
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shown to be hyperactivated in neurofibroma-associated cells without neurofibromin; 
including Akt 
60,96
, mTOR 
97
, p70S6 kinase 
97
, and the small GTPase Rac1/2 
60
.  
While the critical contribution of the Ras/Raf/Mek/Erk pathway to NF1 associated 
phenotypes is well known, the prolonged activation of this pathway is dependent on other 
signals, including PI3-K 
98
.  Work from our laboratory has established that 
pharmacologic inhibition or genetic disruption of PI3-K in Nf1+/- mast cells will reduce 
the SCF mediated hyperactivation of Raf-1, Mek1/2 and Erk1/2 kinase activity in       
vitro  
60
, implying the existence of cross talk between the PI3-K and MAPK pathways.  
Further efforts showed that genetic loss of Rac2, and important downstream target of PI3-
K will correct the hyperactivation of Erk, as well as the gains in proliferation in Nf1+/- 
mast cells 
60
.  However, identification of the mediators downstream of Rac that are 
responsible for the inter-pathway signaling in Nf1+/- mast cell activity is incomplete.  
Elucidation of the specific molecules involved in the hyperactive gain-in-function 
phenotypes associated with Nf1 haploinsufficiency is critical for understanding the 
biochemical mechanisms underlying tumor pathophysiology in NF1. 
 
p21 activated kinases: downstream effectors of Rho GTPases 
 
 The Ras related-Rho family of GTPases (including Rac, Rho, cdc42, among 
others) are molecular switches that regulate a wide variety of cellular activities that are 
important in normal as well as pathological states 
99
.  The Rho GTPase family has roles 
in cellular functions as diverse as cytoskeletal activation and regulation, vesicle transport, 
gene expression, cell cycle transitioning, and oxidant generation 
100
.  Considerable effort 
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has been put forth in identifying the signaling networks downstream of these GTPases 
and their related functions 
101
.  The first kinase proteins known to be regulated by the Rho 
family of GTPases were identified in 1994 in a gel overlay assay for Rac1 binding 
partners, and were termed p21 activated kinases, or Paks 
102
.  The binding partners found 
at 68, 65, and 62 kd were later termed Pak1 (or α-Pak), Pak3 (or β-Pak), and Pak2 (or γ-
Pak), respectively.  Pak1 was found to share 77% identity with Pak2 and 81% identity 
with Pak3 
103
.  Pak proteins interacted only with active (GTP), not inactive (GDP) bound 
Rac or cdc42 
102
.  Furthermore, the intrinsic phosphotransferase activity of Paks on 
myelin basic protein was dramatically increased after interacting with GTP bound Rac or 
cdc42 
104
.  
 Sequence analysis of the Pak proteins showed high homology with the yeast 
Ste20 serine/threonine kinase 
105,106
.  Phylogenetic investigations have revealed that all 
eukaryotic kinomes contain multiple members of the Ste20 family 
106
.  Paks and Ste20 
have a highly conserved catalytic domain located near the C-terminus (amino acid 
residues (aa) 255–529 in PAK 1).  Outside of this catalytic domain, Paks and Ste20 
diverge in sequence, save for a short regulatory region close to the N-terminus.  This 
regulatory region, called the p21 binding domain or PBD (aa 67-113 in Pak1), is very 
highly conserved among all Ste20 proteins and allows for binding with activated Rac or 
cdc42 
105
.  Overlapping with, but not congruent to, the PBD is an autoinhibitory segment 
known as the inhibitory switch (aa 83-149 in Pak1) that regulates basal kinase activity 
107
.  
Other sequence commonalities between Paks1-3 include two N-terminal canonical PXXP 
SH3-binding domains, the first has been shown to interact with the adapter protein Nck 
108
, the second binds to Grb2 
109
; as well as a non-classical PXP SH3-binding domain, 
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known to interact with PIX (also known as Rac/cdc42 GEF6) 
110
.  Furthermore, Pak1 
contains two additional PXXP SH3-binding domains in its N-terminal region that are not 
found in Pak2.     
 Crystal structure of Pak1 revealed it exists as an inactivated homodimer in vivo, 
arranged in a trans-inhibited conformation: the N-terminal autoinhibitory segment of one 
of the dimer partners binds and inactivates the C-terminal catalytic domain of the other 
111
.  Binding of GTP-bound Rac to the PBD of one of the dimer partners disrupts 
dimerization, causing conformational changes that destabilize the inhibitory switch and 
disassociate it from its partner’s catalytic domain 
101
.  Once freed from the dimerized 
state, the kinase domain is capable for catalytic function 
107
.  However, full catalytic 
efficiency and sustained alleviation from reforming autoinhibitory dimers requires 
phosphorylation in the activation loop of the catalytic domain (Thr423 in Pak1) 
112-114
.  In 
addition to phosphorylation at Thr423, Pak1 kinase activity is also upregulated by 
phosphorylation at Ser144, which is located in the inhibitory switch domain 
115
.  Both of 
these residues are known autophosphorylation sites; however, maximal Pak1 kinase 
activity is dependent upon PDK1 phosphorylation of Thr423 after Rac/cdc42 binding 
113,116
.   
 Although Pak proteins are primarily thought of and initially discovered as 
downstream effectors of Rac and cdc42, GTPase independent activation has also been 
described.  The SH3-binding domains in the N-terminal region allow for membrane 
recruitment by Nck and Grb2, which leads to induction of Pak kinase activity 
117-119
.  
Also, Paks are autophosphorylated and activated following certain protease        
treatments 
120
.  For example, Pak2, but not Pak1, is constitutively activated following 
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cleavage by caspase 3 at Asp212 during apoptosis 
121
.  Lipids such as sphingosine and 
sphingosine derived lipids, gangliosides, and phosphatidic acids all are known to activate 
Pak1 independent of GTPase binding 
122
.  The understanding of the physiologic 
importance of lipid activation relative to GTPase activation of Pak1 is incomplete at best. 
Despite having high affinity for myelin basic protein and histone H4 in in vitro 
kinase assays, it is unlikely that Pak1 phosphorylates these proteins in physiologic 
systems 
115
.  Biochemical studies have indicated that Pak1 is a “basic directed” kinase, 
with a (K/R)RXS target sequence for phosphorylation 
123
.  This is a similar 
phosphorylation sequence to proteins such as PKA and PKC; however, an acidic residue 
at the -1 position is well tolerated by Pak but not by PKA and PKC 
123
.  In addition, Pak1 
cannot tolerate proline residues at -1 or +1 positions, which are required critical for 
substrate phosphorylation by proline directed kinases such as MAPKs and cdc2, 
123
 
indicating that Pak1 and proline-directed kinases do not share phosphorylation targets.     
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Figure 1- Structure of Pak1.  A) Schematic representation of relevant domains in 
primary structure of Pak1.  The PXXP SH3-binding sites of Pak1 for the adaptors Nck 
and Grb2, the PXP SH3-binding site for the exchange factor PIX, and the PBD for the 
GTPases Cdc42 and Rac1 are shown.  B) Diagram of conformational changes induced 
upon activation by GTPases.  The inactive state is a trans-inhibited dimer.  The IS domain 
overlaps portions of the PBD, regulates the dimerization of Pak1 and inhibits the kinase 
activity of the other member of the Pak1 homodimer.  GTPase binding to the PBD leads 
to conformational changes of the IS domain, releasing the Pak1 homodimer.  The active 
state is a monomer whose open conformation is stabilized by auto-phosphorylation.  This 
figure was first published in its original form by M.C. Parrini, et al. in Biochem. Soc. 
Trans. 33, 646-648 (2005). 
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Pak is a multifunctional signal transducer 
 
 Pak1 is well described as a modulator of cytoskeletal dynamics.  
Immunofluorescence analysis of cells stimulated with agents such as PDGF, insulin, and 
transformation by v-src revealed subcellular localization of Pak1 into cortical actin 
structures 
124
.  This interaction with the cytoskeleton helps regulate motility, as 
expression of dominant negative Pak1 lead to decreased migration of NIH-3T3 cells, with 
associated loss of organized actin structures 
125
.  Conversely, overexpression of 
constitutively active Pak1 lead to increases in both motility as well as large actin 
structures at the leading edge 
125
.  Pak1 has a number of downstream targets that regulate 
actin organization and polymerization, including filamin A, which leads to crosslinking 
of filamentous actin into orthogonal networks at the membrane 
126
; and LIM kinase, 
which inactivates the F-actin destabilizing protein cofilin, leading to aggregation of F-
actin fibers 
127
.  Pak can also regulate microtubule dynamics through its inactivation of 
the microtubule destabilize stathmin 
128
.  One working model of Pak and its critical role 
in regulating cell motility describes Pak1 being activated by Rac and cdc42 near the 
leading edge of the cell after chemotactic stimulation, leading to stabilization of actin 
structures after activating Filamin A and inhibiting cofilin (via LIM kinase) and 
maintenance of growing microtubule structures by inhibition of stathmin 
101
.   
 In addition to regulating the cytoskeleton, Pak has an important role in regulating 
activation of MAPK signaling pathways.  This role was initially suggested from the fact 
that Ste20 is known to act as a MEKK (MAPK/Erk kinase kinase) in yeast pheromone 
signaling 
106
.  Pak1 directly activates Raf-1, by phosphorylating serine residue 338 
129
.  
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Phosphorylation of Ser338 is critical for full activation of Raf-1 kinase activity 
130
.  In 
addition, Pak1 also directly activates MEK1, phosphorylating serine 298 
131
.  Serine 298 
is important for “priming” MEK1 for activation by increasing Raf-1 kinase activity 
toward Ser217/221 on MEK, leading to increased Mek kinase activation 
132
.  
Furthermore, transfection of siRNA to Pak1 greatly reduced Erk activation by PDGF in 
NIH-3T3 cells, associated with congruent decreases in Raf and Mek activity 
133
.  The 
phosphorylation of Pak1 targets on Raf-1 (Ser338) and Mek1 (Ser298) can increase 
efficiency of Erk activation by facilitating protein-protein interactions and result in 
increased responses to low-level stimuli 
134
.   
 Besides activating the Erk MAPK, overexpressed Pak1 has also been reported to 
activate p38 MAPKs 
135,136
.  Overexpression of constitutively active Pak1 increases p38 
kinase activity following phosphorylation at Thr180 
136
.  p38 activity following growth 
factor stimulation is linked to the migration of numerous cell types; overexpression of 
dominant negative Pak1 impedes p38 dependent migration in smooth muscle cells 
137
  
and macrophages 
138
.  Unlike the well described interactions between Pak1 and the 
Raf/Mek/Erk pathway, the manner in which Pak1 effects p38 is incompletely understood.  
p38 is not a direct target of Pak1 kinase activity, and the exact mechanism of how Pak1 
leads to increased p38 activity is unclear.  Even less understood is the relationship 
between Pak1 and JNK.  Overexpression of Pak1 has produced reports that indicate both 
enhanced 
135,139,140
 as well as impaired 
141,142
 JNK activity.  Pak/JNK interactions may be 
cell type specific, and as with p38, the nature of these inchoate interactions requires 
further examination 
101
. 
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 In multiple cellular systems, Pak1 has been reported to be a member of an anti-
apoptotic signaling network via its interactions with Bad 
143-146
.  Bad is a death promoting 
Bcl-2 family member that binds to Bcl-2 and Bcl-xL, preventing their anti-apoptotic 
activities 
146
.  However, after phosphorylation, Bad is unable to associate with Bcl-2 or 
Bcl-xL, and instead is sequestered by the 14-3-3 cytosolic adapter protein.  Pak1 
phosphorylates Bad at Ser112 and Ser136 in vitro and in vivo, leading to decreased 
association of Bad with Bcl-2 and Bcl-xL and corresponding decreases in apoptosis 
following stimulation with survival signals 
143
. 
 
Cancer and Pak1 
 
 In recent years, Pak1 activity has been linked to the development of an extremely 
wide variety of human cancers, including: breast 
145,147-149
, melanoma 
150
, glioblastoma 
151
, bladder 
152
, kidney 
153
, ovarian 
154
, liver 
155
, colorectal 
156
, and pancreatic 
157
.  The role 
of Pak1 in carcinomas of the breast is very well documented.  Initial reports described 
PI3-K/Pak1 dependent reorganization of the actin cytoskeleton following heregulin 
stimulation, leading to increased migration of breast cancer cells 
158
.  More recent reports 
have focused on overexpression of Pak1 in breast cancer cells, particularly in the nucleus, 
resulting in increased phosphorylation of the estrogen-receptor alpha and subsequent 
progressive tamoxifen resistance 
159
. 
 In addition, Pak1 activity has been linked to oncogenic processes in cell types 
relevant to neurofibromas.  Pak1 initially drew attention with regards to NF1 due to the 
fact that Pak1 can induce many cellular functions similar to those caused by activated 
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Ras.  In Rat-1 fibroblasts, kinase dead Pak1 reduced oncogenic transformation mediated 
by overexpression of K-Ras by over 90% in soft-agar foci assays 
160
.  This result was 
linked to the decreased Erk activation found in the Rat-1 cells that co-expressed K-Ras 
and kinase dead Pak1 
160
.  In a similar manner, expression of dominant negative Pak1 in 
rat Schwann cell lines prevented Ras-mediated transformation 
161
.  Using a NF1
-/-
 
Schwann cell line taken from a NF1 patient, mouse xenograft experiments revealed that 
in vivo tumorigenicity could be greatly reduced by transfecting the NF1 null Schwann 
cells with kinase dead Pak1 prior to implantation 
161
.  Other groups using FK228, an 
inhibitor of the histone deacetylase complex that reduces Pak1 kinase activity, have 
shown that treatment of mice with FK228 causes the complete regression of xenografts 
resulting from MPNST cells derived from NF1 patients 
162
.  Importantly, Nf1
+/-
 mast cells 
that have been stimulated with SCF have increased Pak1 kinase activity 
60
.  Given this 
finding and the critical role ascribed to Rac in regulating Nf1 haploinsufficient gains-in-
function, Pak1 is an appealing candidate gene for modulating the hyperactive MAPK 
signaling in cells of the tumor microenvironment that allows neurofibroma progression. 
 
Thesis overview 
 
Identification of the specific mediators downstream of hyperactive Ras is critical 
for understanding the biochemical mechanisms underlying the abnormal cell phenotypes 
that contribute to the pathophysiology of neurofibromas in NF1.  Studies described here 
examine the role of Pak1 in regulating aberrant Ras signaling in cells that have 
disruptions in Nf1.  The aims of this work are threefold, first to evaluate the role of Pak1 
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as an effector of SCF mediated gain-in-function phenotypes associated with Nf1 
haploinsufficiency in mast cells in vitro and in vivo.  Second, we use a conditional Nf1 
knockout animal disease model to determine the significance of Pak1 disruption in the 
development of Nf1 deficient neoplasia such as a plexiform neurofibroma.  And third, we 
examine if Pak1 loss has functional consequences in PDGF and TGF-β mediated 
signaling events and cellular functions in fibroblasts.  We expect that these studies will 
provide unique insights into the pathophysiology of NF1 and highlight Pak1 as a possible 
drug target for the treatment of the disease. 
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Figure 2- Schematic representation of signaling events associated with Nf1 
haploinsufficiency.  Ras is activated by the binding of SCF to its receptor c-Kit, which 
activates a number of GEFs that catalyze the conversion of inactive Ras-GDP to active 
Ras-GTP.  Disruptions at Nf1 prevent the normal conversion of active Ras back to its 
inactive state, leading to its hyperactivation.  Hyperactive Ras in turn recruits and 
activates the MAPK effector pathway that ultimately increase many cellular functions, 
including proliferation, migration, and degranulation.  These gains-in-function and 
increases in MAPK signaling are dependent upon Ras activation of PI3-K/Rac.  The 
signaling events downstream of Rac that lead to MAPK hyperactivation are incompletely 
understood. 
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MATERIALS AND METHODS 
 
ANIMALS 
Nf1
+/
- mice were obtained from Tyler Jacks at the Massachusetts
 
Institute of 
Technology (Cambridge, MA) in a C57BL/6.129 background
 
and backcrossed for 13 
generations into the C57BL/6J strain.  Pak1 -/- mice were generated in Dr. Jonathan 
Chernoff’s Laboratory (Temple University) and are backcrossed six generations to be on 
a C57BL/6J strain.  These studies were conducted with a protocol approved
 
by the 
Indiana University Laboratory Animal Research Center.
  
The Nf1 allele was genotyped as 
described previously 
163
.  The Pak1 allele was genotyped by PCR using the following 
primers: Pak 1 Forward=GCCCTTCACAGGAGCTTAATGA, Pak 1 Reverse: 
GAAAGGACTGAATCTAATAGCA, neoReverse: CATTTGTCACGTCCTGCACGA 
set up in two separate reactions (one for WT and one for KO band) PCR program Pak1:  
94 2 min, 94 20s (92 for KO reaction), 52 (58 for KO reaction) 20s X 35 cycles, 71 2min, 
71 7 min, 4 48 hr.  WT Reaction, yields a 240 bp band; KO reaction, yields a 360 bp 
band.  Multiple F0 founders were used to generate the four Nf1 and Pak1 genotypes used 
in these experiments as
 
outlined.  F0: Nf1+/-; Pak1+/+ x Nf1+/+; Pak1-/-.  F1: Nf1+/-; 
Pak1+/-
  
x Nf1+/+; Pak1+/-.  F2: Nf1+/-; Pak1-/-, Nf1+/+; Pak1-/-, Nf1+/-; Pak1+/+, Nf1
 
+/+; Pak1+/+. 
 
BONE MARROW MAST CELL CULTURE  
  BMMCs were cultured in RPMI (Gibco BRL) supplemented with 10% fetal calf 
serum (HiClone), 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2% 
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penicillin/streptomycin
 
(BioWhittaker) and 5 ng/mL IL-3 (Peprotech).  Cells were cultured in 
a 37°C,
 
5% CO2, humidified incubator.  All proliferation, migration, and biochemical assays 
utilized BMMCs that had been in culture between four to eight weeks.  All experiments
 
were 
conducted using at least three independent lines from each genotype. 
 
MAST CELL PROGENITOR ASSAY 
 Using an established methylcellulose culture based method 
164,165
, we determined the 
in vitro mast cell colony forming ability of Pak1-/- and Nf1+/-;Pak1-/- bone marrow.  Briefly, 
whole marrow from both femurs and tibias were collected from animals and pooled.  LDMNC 
were isolated using Histopaque 1119 (Sigma Aldrich) and counted using a hemocytometer.  
2x10
4
 cells were then plated in 1mL methylcellulose containing 20% fetal calf serum 
(HiClone), 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2% 
penicillin/streptomycin
 
(BioWhittaker), 2.5ng/mL IL-3 (Peprotech), and 10ng/mL SCF 
(Peprotech).  After 21 days growth in a 37°C,
 
5% CO2, humidified incubator, the surviving 
mast cell colonies were counted and are expressed as number of mast cell colonies per animal.  
Assays were performed in triplicate. 
 
MAST CELL MATURATION 
 Maturation of cultured bone marrow mast cells was assayed by the expression levels 
of c-Kit and FcεRI using fluorescence cytometry as described in other reports 164.  4-week-old 
mast cell cultures were blocked with unconjugated anti-FcγRII/III (BD Pharmingen) and 
washed.  This was followed by incubation with anti-DNP monoclonal antibody IgE clone 
SPE-7 (Sigma Chemical Co), anti-mouse CD 117 (c-kit) PE conjugated antibody (BD 
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Pharmingen), and FITC conjugated anti-mouse IgE (BD Pharmingen) secondary antibody.  
Cells were then washed to remove unbound antibodies and resuspended in 0.5% BSA PBS 
Buffer.  Aliquots of mast cells were also stained with FITC and PE conjugated rat IgG2b,Κ 
isotype antibodies to serve as negative controls.  Cells were analyzed by FACS
TM
.  Cells that 
were double positive for both c-kit and FcεRI were considered to be mature and suitable for 
use in in vitro experiments. 
 
MAST CELL IMMUNOBLOTTING 
Whole cell protein extracts were obtained
 
from SCF stimulated BMMC in lysis 
buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA pH 8.0, 1% Triton X-100, 1mM 
PMSF, 1mM NaF, 1mM Na3VO4, 10% glycerol and Complete protease inhibitor), and 
equivalent amounts
 
of protein were electrophoresed on 10% SDS-PAGE gels, transferred
 
to nitrocellulose membranes (Amersham Biosciences),
 
and detected by Western blotting 
using the ECL Plus system (Amersham
 
Biosciences).  Antibodies used were Phospho-
p44/42 MAPK (Thr202/Tyr204) (197G2) Rabbit mAb (Cell Signaling Technology), 
p44/42 MAP Kinase Antibody (Cell Signaling Technology) Phospho-MEK1/2 
(Ser217/221) Antibody (Cell Signaling Technology), Anti-MEK1, NT (Upstate), 
Phospho-MEK1/2 (Ser298) Antibody (Biosource International) Anti-phospho-Raf-1 
(Ser338) (Upstate), Monoclonal β-actin antibody (clone AC-15) (Sigma-Aldrich). 
 
MAST CELL PROLIFERATION ASSAY  
Proliferation
 
assays were performed as described previously 
59
.  Briefly, BMMCs 
from
 
each genotype were deprived of growth factors for 24 h, and treated with 10µM 
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Mek1 inhibitor PD98059 (Biosource International), 10µM p38 MAPK inhibitor 
SB203580 (Biosource International) or DMSO for 2h prior to stimulation.
  
3 x 10
5
 cells 
were plated in 24-well dishes in 1 ml RPMI containing 10% fetal calf serum,
 
1% 
glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2% penicillin/streptomycin
 
(BioWhittaker), and 50 ng/ml SCF
 
(PeproTech) or no growth factors as indicated in a 
37°C,
 
5% CO2, humidified incubator.  After 72 h, cells were counted using a 
hemocytometer.
  
Cell viability was determined by a trypan blue exclusion assay.
  
Assays 
were performed in triplicate. 
 
MAST CELL HAPTOTAXIS ASSAY 
To evaluate mast cell migration, a transwell haptotaxis assay was used as 
previously described 
164,166
.  2.5x10
5
 cells were resuspended in 100 µl RPMI with 10µM 
Mek1 inhibitor PD98095 (Biosource International), 10µM p38 MAPK inhibitor 
SB203580 (Biosource International) or DMSO for 2h prior to stimulation.  These cells 
were loaded onto transwell filters (8mm pore filter Transwell, 24 well cluster; Costar) 
that were coated with recombinant fibronectin fragment (Retronectin CH296, Takara), 
which then were placed in wells containing 600 µl of serum free RPMI supplemented 
with 25ng/mL SCF.  After four hours of incubation at 37
o
C in 5% CO2, non-migratory 
cells on the upper membrane surface were removed with a cotton swab, and migrated 
cells attached to the bottom surface of the membrane were stained with 0.1% crystal 
violet in 0.1 M borate, pH 9.0, 2% ethanol for 10 minutes at room temperature.  The 
average number of migrated cells per higher-power field was counted with an inverted 
microscope using the 20x objective lens.  Assays were performed in triplicate. 
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F-ACTIN QUANTITATION 
 To evaluate F-actin content, BMMCs were pre treated with inhibitors and 
stimulated as described above for migration assays.  After 30 minutes of incubation at 
37
o
C in 5% CO2 cells were removed from the upper chamber of the transwell and placed 
into 3.7% formaldehyde solution for fixation.  Fixed cells were treated with 0.01% Triton 
X-100 (Sigma-Aldrich) in PBS for 5 minutes at 25
o
C, washed, and then incubated with 
160nM Alexa Fluor 488 Phalloidin (Invitrogen) for 20 minutes at 25
o
C prior to FACS 
analysis by fluorescence cytometry.  A minimum of 10,000 mast cell events were 
recorded, and the results are reported as the fold increase in mean channel fluorescence 
from unstimulated cells.  Assays were performed in triplicate. 
 
CONFOCAL MICROSCOPY 
 To evaluate F-actin organization, BMMCs were pre treated with inhibitors and 
stimulated as described above for migration assays.  After 30 minutes of incubation at 
37
o
C in 5% CO2 cells were removed from the upper chamber of the transwell and were 
placed into cytospin chambers for centrifugation onto microscope slides.  The slides were 
placed into 3.7% formaldehyde solution for fixation.  Fixed cells were treated with 0.01% 
Triton X-100 (Sigma-Aldrich in PBS for 5 minutes at 25
o
C, washed, and then incubated 
with 160nM Alexa Fluor 488 Phalloidin (Invitrogen) for 20 minutes at 25
o
C prior to 
mounting with DAPI.  Cells were then analyzed via confocal microscope with the Zeiss 
UV LSM-510 system.  Quantization of the fluorescent intensity of the confocal image 
was analyzed using NIH ImageJ software. 
 30 
 
MAST CELL DEGRANULATION ASSAY 
Measurements of in vitro degranulation of mast cells are proposed using a β-
hexosaminidase release assay as previously described 
167,168
.  Four to six weeks after initiation 
of culture, BMMCs were washed and sensitized for 2 hours at 2 x 10
6
 cell/ml in 0.5% BSA 
RPMI 1640 containing 1.5 µg/ml of anti-DNP IgE monoclonal antibody (clone SPE-7, Sigma 
Chemical Co).  Excess antibody was removed and cells were resuspended at 2 x 10
6
 cells/ml 
in Tyrode’s buffer (10 mM HEPES buffer, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1mM 
MgCl2, 5.6 mM glucose, and 0.05% BSA, ph=7.4).  Sensitized BMMCs were then stimulated 
with 30ng/ml dinitrophenyl conjugated to human serum albumin (DNP-HSA) (Sigma 
Chemical Co.) and 25ng/ml SCF for 15 minutes at 37
o
C.  The cell pellet was solubilized in 
Tyrode’s buffer, 0.5% Triton X-100.  b-hexosaminidase release was measured in both the 
supernatant and the cell pellet by incubating with 4-Nitrophenyl N-acetyl-beta-D-
glucosaminide (p-nitrophenyl-N-acetyl-b-D-glucosamine) prepared in sodium citrate (pH 4.5) 
for one hour at 37
o
C.  A 0.1 M Sodium carbonate/sodium bicarbonate buffer (pH 10) was 
used to stop the reaction and the assay was read at 405 nm.  Degree of degranulation was 
reflected as a percent of b-hexosaminidase released = (OD of supernatant)/ (OD of total 
(supernatant + pellet)) x 100.  Assays were performed in triplicate. 
 
MAST CELL SURVIVAL ASSAY 
To examine the effect of Pak1 loss on the survival of Nf1+/- mast cells in response to 
SCF, mast cells cultured as above were deprived of growth factors for 24 hours, and 5x10
5
 
cells were plated in 24-well dishes with serum free RPMI containing 1% glutamine 
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(BioWhittaker), 1.5% HEPES (BioWhittaker), and 2% penicillin/streptomycin
 
(BioWhittaker) 
supplemented with 50ng/ml of SCF.  The number of surviving cells was determined by trypan 
blue exclusion at 48 hours of culture post stimulation in a 37°C,
 
5% CO2, humidified 
incubator.  The number of apoptotic cells was measured by using the Annexin V-FITC 
Apoptosis detection kit (BD Pharmingen) and FACS analysis.  Cells that stained double 
positive for both Annexin V and PI were counted as apoptotic.  Assays were performed in 
triplicate.  
 
IN VIVO MAST CELL ACCUMULATION ASSAY 
 Adapting methods described previously 
169
, Adult Nf1+/-; Pak1-/-, Nf1+/+; Pak1-/-, 
Nf1+/-; Pak1+/+, Nf1
 
+/+; Pak1+/+ mice
 
received a continuous infusion of various doses 
of SCF or
 
vehicle (PBS) from microosmotic pumps (Alzet) placed under the
 
dorsal back 
skin.  Osmotic pumps were surgically placed under
 
light avertin anesthesia.  SCF or 
vehicle was released over
 
7 d at a rate of 0.5 µl/hour, and osmotic pumps were surgically
 
removed on day 7 after sacrifice by cervical dislocation.  To
 
accurately identify cutaneous 
sections for quantitating changes
 
in mast cell numbers in response to SCF, the dorsal skin 
was
 
stained with a drop of Davidson Marking System green tissue dye at the point of 
exit of SCF
 
from the osmotic pump before removal of the pump.  3-cm sections
 
of skin 
marked with tissue dye were removed, fixed in buffered
 
formalin, and processed in 
paraffin-embedded sections.  Specimens
 
were stained with hematoxylin and eosin to 
assess routine histology
 
and with Giemsa to identify mast cells.  Cutaneous mast cells
 
were quantitated in a blinded fashion by counting 2-mm
2
 sections
 
in proximity to the 
tissue dye stain.  Cells were considered degranulated if there was a change from their 
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normal compacted and granular appearance resulting in an extensive dispersion of more 
than 15 extruded vesicles localized near the cell, or when there was an extensive loss of 
granule staining, giving the cell a “ghostly” or “hollow” look 
170
. 
 
Nf1 CONDITIONAL KNOCKOUT ADOPTIVE TRANSFER 
 
 Krox20Cre;Nf1flox/flox and Krox20Cre;Nf1flox/- mice were used as recipients to 
see if the adoptive transfer of Nf1+/-;Pak1-/- hematopoietic system would alter the 
development or progression of plexiform neurofibromas.  Briefly, 5x10
6
 whole bone 
marrow cells from either Nf1+/- or Nf1+/-;Pak1-/- mice were transplanted via tail vein 
injection into 6-8 week old Krox20Cre;Nf1flox/flox and Krox20Cre;Nf1flox/- mice after 
the recipients had been treated with a split dose of 1100 rads of ionizing radiation (700 
rads followed by 400 additional rads 5 hours later).  These animals were followed for 
over one year to assess the development of plexiform neurofibromas in the spinal nerve 
roots.  
 
GENERATION OF Krox20Cre;Nf1flox/-;Pak1-/- ANIMALS 
 Krox20Cre;Nf1flox/-  mice on a C57BL/6J strain were intercrossed with Pak1-/-  
mice also on a C57BL/6J strain.  These animals were followed for over a year to assess to 
assess the development of plexiform neurofibromas in the spinal nerve roots.  These 
studies were conducted with a protocol approved
 
by the Indiana University Laboratory 
Animal Research Center.   
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DORSAL ROOT GANGLION DISSECTION AND MEASURMENT 
Immediately following sacrifice induced by CO inhalation, whole mice were 
perfused and fixed in 4% paraformaldehyde.  The dorsal root ganglia and peripheral 
nerves were then dissected out under a dissection microscope.  To evaluate the size of the 
dorsal root ganglion, an anatomic measurement of the dorsal root ganglia from the sciatic 
nerve was performed using calipers to measure the ganglion’s widest and longest 
dimensions.  Using a formula which approximates spheroidal volume (0.52 x (width)
2
 x 
(length)), the volume of the ganglia was determined. 
 
HISTOLOGIC ANALYSIS OF DORSAL ROOT GANGLIA 
To make detailed observations about the cellular composition and morphology of 
the dorsal root ganglia, paraffin sections were stained with hematoxylin and eosin (H&E).  
Given collagen accounts for approximately 60% of the dry weight of human plexiform 
neurofibromas, the tissue sections were also stained with Masson trichrome to identify 
collagen deposition.  Additionally, to identify the presence of mast cells in the tissue, 
Alcian blue staining was performed. 
 
GENERATION AND CULTURE OF PRIMARY FIBRBLASTS 
 Using an established method 
75
, fibroblasts were derived from 13.5 days post 
coitus embryos of WT and Pak1-/- mice.  Cells were maintained in culture using high 
glucose DMEM (Gibco BRL) supplemented with 10% fetal calf serum (HiClone), 1% 
glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), and 2% penicillin/streptomycin
 
(BioWhittaker).  Cells were cultured in a 37°C,
 
5% CO2, humidified incubator.  All 
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assays utilized fibroblasts were from passage two to four.  For all cellular and 
biochemical assays, fibroblasts were stimulated with human recombinant PDGF-BB 
(PeproTech) or human recombinant TGF-β (PeproTech).  All experiments were 
conducted using at least three independent lines from each genotype. 
 
FIBROBLAST PROLIFERATION ASSAY 
 
[3H]
Thymidine incorporation assays were used to examine fibroblast proliferation, 
in a manner described previously 
71
.  Briefly, fibroblasts were plated at a concentration of 
2x10
4
 cells in 200µL of media containing 10% fetal calf serum per well in 96 well tissue 
culture treated plates.  After 24 hours, the cells were washed and media was replaced 
with DMEM without serum containing PBS as a vehicle controls, 50ng/mL PDGF-BB, or 
2ng/mL TGF-β and incubated at 37°C  in a 5% CO2, humidified incubator.  After 36 
hours tritiated thymidine (PerkinElmer Life and Analytical Sciences) was added to each 
well 6 hours prior to harvest on glass filter fibers (Packard Instrument) and β-emission 
was measured.    
 
FIBROBLAST WOUND HEALING ASSAY 
 To assess the migration of fibroblasts, we used an established wound healing 
assay protocol 
71
.  1x10
5
 cells in 1mL of media containing 10% fetal calf serum were 
plated in a 12 well plate.  After 24 hours, the cells were washed and media was replaced 
with DMEM without serum before incubation at 37°C
  
in a 5% CO2, humidified 
incubator.  After 16 hours, the cells were washed and treated with 10µg/mL of 
Mitomycin C (Sigma-Aldrich) for 1 hour.  The cells were then washed, and media was 
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replaced with DMEM without serum containing PBS as a vehicle control, 50ng/mL 
PDGF-BB, or 2ng/mL TGF-β.  A wound was created using a plastic pipette tip across the 
diameter of the well, and the cells were incubated for 12 hours at 37°C and followed by 
time-lapse microscopic photography.  After incubation, cells were stained with crystal 
violet solution, and the number of cells that invaded the wound was determined by using 
ImageJ (NIH) software. 
 
FIBROBLAST COLLAGEN PRODUCTION ASSAY 
 To examine collagen production by fibroblasts after stimulation by PDGF-BB or 
TGF-β, the SircolTM soluble collagen assay was used.  Confluent fibroblast cultures on 
10cm tissue culture dishes were stimulated for 48 hrs with PBS as a vehicle control, 
50ng/mL PDGF-BB, or 2ng/mL TGF-β.  After stimulation, 200µL of the media were 
incubated with the Sircol
TM
 dye reagent.  Dye collagen complexes were resolublized by 
addition of alkali reagent and OD readings were made on a microplate reader at a 
wavelength of 540nm.    
 
FIBROBLAST APOPTOSIS ASSAY 
 To determine the effects of PDGF-BB and TGF-β on fibroblast survival, TUNEL 
staining with the APO-DIRECT
TM
 kit (BD Pharmingen) was used.  1x10
5
 cells in 2mL of 
media containing 10% fetal calf serum were plated on a 6 well plate.  After 24 hours, the 
cells were washed and media without serum containing PBS as a vehicle control, 
50ng/mL PDGF-BB, or 2ng/mL TGF-β was added.  After 72 hours, the cells were 
removed from the wells by treatment with 0.1% Trypsin-EDTA (Gibco BRL) and fixed 
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in a 1% w/v paraformaldehyde in PBS.  After fixation, the cells were stained with the 
APO-DIRECT
TM
 kit components and analyzed by flow cytometry. 
 
CONFOCAL ANALYSIS OF FIBROBLAST ACTIN CYTOSKELETON 
 To evaluate the F-actin cytoskeleton in fibroblasts, cells were prepared and 
stimulated as described above for wound healing assays, with the fibroblasts on 
coverslips rather than tissue culture plates.  After 4 hours of incubation at 37
o
C in 5% 
CO2, the fibroblast covered coverslips were placed into 3.7% formaldehyde solution for 
fixation.  Fixed cells were treated with 0.01% Triton X-100 (Sigma-Aldrich in PBS for 5 
minutes at 25
o
C, washed, and then incubated with 160nM Alexa Fluor 488 Phalloidin 
(Invitrogen) for 20 minutes at 25
o
C prior to mounting with DAPI.  Cells were then 
analyzed via confocal microscope with the Zeiss UV LSM-510 system. 
 
FIBROBLAST IMMUNOBLOTTING 
Whole cell protein extracts were obtained
 
from fibroblasts stimulated with 
50ng/mL PDGF-BB, or 2ng/mL TGF-β in lysis buffer (50mM Tris pH 7.4, 150mM 
NaCl, 2mM EDTA pH 8.0, 1% Triton X-100, 1mM PMSF, 1mM NaF, 1mM Na3VO4, 
10% glycerol and Complete protease inhibitor), and equivalent amounts
 
of protein were 
electrophoresed on 10% SDS-PAGE gels, transferred
 
to nitrocellulose membranes 
(Amersham Biosciences),
 
and detected by Western blotting using the ECL Plus system 
(Amersham
 
Biosciences).  Antibodies used were Phospho-p44/42 MAPK 
(Thr202/Tyr204) (197G2) Rabbit mAb (Cell Signaling Technology), p44/42 MAP 
Kinase Antibody (Cell Signaling Technology), Phospho-Cofilin (Ser3) polyclonal 
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antibody (Cell Signaling Technology), Cofilin polyclonal antibody (Cell Signaling 
Technology), Phospho-Filamin A (Ser2152) polyclonal antibody (Cell Signaling 
Technology), Filamin A polyclonal antibody (Cell Signaling) Monoclonal β-actin 
antibody (clone AC-15) (Sigma-Aldrich). 
 
IN VIVO FIBROBLAST INVASION ASSAYS 
 Adapting a method described previously 
71,171
, we used a Cultrex
TM
 plug assay to 
evaluate the invasion of fibroblasts in vivo in response to PDGF-BB or TGF-β.  The 
Cultrex
TM 
media (R&D Systems) was thawed at 4
o
 for 24h and mixed with PBS as a 
vehicle control, 200ng.mL PDGF-BB, or 10ng/mL TGF-β.  300µL of vehicle containing 
Cultrex
TM 
or 300µL of growth factor containing CultrexTM were injected subcutaneously 
into the left or right groin of WT or Pak1-/- mice, respectively.  The plug was removed 
on day 7 and was frozen immediately on dry ice.  Tissues were sectioned and stained 
with H&E to assess histology.  The number of invaded cells per high power field was 
quantitated by using ImageJ software.  At least 3 mice per genotype were examined. 
 
BLEOMYCIN INDUCED PULMONARY FIBROSIS MODEL 
 Harrison 
172
 described a model system where continuous release of bleomycin 
sulfate would induce a fibrotic reaction in mice that mimicked human pulmonary disease.  
We implanted microosmotic pumps (Alzet) containing PBS or 125mg/kg/day bleomycin 
subcutaneously in the dorsum of lightly anesthetized WT and Pak1-/-mice.  28 days after 
surgery, mice were sacrificed, broncheoalveolar lavage was performed and the lungs 
removed.  The right lung was minced and used to assess total collagen content using the 
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Sircol
TM
 collagen assay described above.  The left lung was fixed in 1% formalin and 
sectioned for histological analysis.  Both H&E to assess structure and Masson’s 
Trichrome to assess collagen deposition were performed. 
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RESULTS 
 
ROLE OF Pak1 IN REGULATING STEM CELL FACTOR DEPENDENT 
FUNCTIONS IN Nf1 HAPLOINSUFFICIENT MAST CELLS 
 
Generation of a Pak1 knockout mouse 
 
In order to study the effects of Pak1 loss in primary cells, a Pak1
-/-
 mouse was 
generated by targeted disruption of the Pak1 allele in embryonic stem (ES) cells (J.D. 
Allen and D.W. Clapp, submitted for publication).  The resultant allele contains a 
neomycin cassette and is lacking 2 kb of genomic DNA encoding the p21-binding 
domain (Figure 3a).  Pak1
-/-
 mice are observed at the predicted Mendelian frequency and 
are viable and fertile.  Pak1
-/-
 mice have a normal lifespan and no noted hematopoietic 
defects.  To verify that Pak1
-/-
 mice produce no Pak1 protein, cell lysates isolated from 
WT and Pak1
-/-
 BMMCs were subjected to Western blot using a Pak1 specific antibody 
(Figure 3b).  To further document the absence of Pak1 protein being expressed at levels 
below detection of Western blot, RT-PCR was conducted to look for expression of the 
Pak1 mRNA transcript.  As expected, Pak1 mRNA was detected in WT BMMCs, but no 
Pak1 mRNA was detected in Pak1
-/-
 BMMCs (Figure 3c).    
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Figure 3- Targeted disruption of the Pak1 allele.  A) Partial restriction map of the 
native Pak1 gene (genomic locus), the targeting vector replacing the coding sequence of a 
portion of the N-terminus, including the p21-binding domain (PBD) and the inhibitory 
domain (ID) with the Neo-resistance gene in the anti-sense orientation (targeting vector), 
and the organization of the targeted Pak1 allele (targeted allele).  The 1 kb genomic probe 
used for screening is indicated along with the expected sizes of the wild type (WT) and 
targeted HindIII fragments.  B) Western blot analysis.  WT and Pak1
-/-
 bone marrow-
derived mast cell (BMMC) lysates were subjected to immunoblotting with anti-Pak1.  
The 68 kDa Pak1 protein is present in WT BMMCs and absent in the Pak1
-/-
 cells.  C) 
RT-PCR analysis.  After reverse transcription of isolated mast cell RNA, Pak1 cDNA 
was amplified by PCR from BMMCs to generate a 352 base pair fragment 
(corresponding to base pairs 306-658) in the WT cells, which is absent in the Pak1
-/-
 
cells.  GAPDH mRNA in WT and Pak1
-/-
 BMMCs is also shown.   
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Intercross of Nf1
+/-
 and Pak1
-/-
 mice 
 
To test our hypothesis that Pak1 is an important mediator of hyperactive Ras 
signaling, we designed a breeding strategy to intercross Nf1
+/-
 mice with Pak1
-/-
 mice to 
generate Nf1
+/-
:Pak1
-/- 
double mutant mice (Figure 4).  Initial breedings of multiple 
C57BL/6 Nf1
+/-
 and Pak1
-/- 
founders generated Nf1
+/-
;Pak1
+/-
 and Pak1
+/-
 progeny.  
Intercrossing of the Nf1
+/-
;Pak1
+/-
 mice from the F1 generation yielded four F2 genotypes 
that were used to generate mast cells for cellular and biochemical assays: Nf1
+/+
;Pak1
+/+
 
(wild type or +/+), Nf1
+/-
, Pak1
-/-
, and Nf1
+/-
:Pak1
-/-
. 
 
Loss of Pak1 reduces numbers of mast cell colonies  
 
 Nf1
 
haploinsufficient mice have a characteristic increase in mast cell progenitors 
compared to wild type controls 
59
.  While genetic disruption of Pak1 does not cause any 
frank disruption of hematopoiesis, we were interested to see if Pak1 loss would affect the 
colony forming ability of mast cell progenitors.  2x10
4
 low-density mononuclear cells 
(LDMNC) from bone marrow were cultured in methylcellulose with growth factors for 
21 days to generate mast cell colonies and then scored.  As expected, more mast cell 
colonies were found in Nf1
+/- 
cultures than wild type cultures (Figure 5).  Loss of Pak1 
caused a significant decrease in the number of mast cell forming units compared to wild 
type controls.  Additionally, Nf1
+/-
:Pak1
-/-
 LDMNC generated significantly fewer mast 
cell colonies compared to Nf1
+/-
 cultures, close to a level seen in wild type controls.       
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Figure 4- Genetic intercross of Nf1
+/-
 and Pak1
-/-
 mice.  The four F2 genotypes 
generated (+/+; Nf1
+/-
; Pak1
-/-
; and Nf1
+/-
;Pak1
-/-
) were used to generate BMMCs for use 
in in vitro biochemical and cellular assays as well as in vivo whole animal studies to 
investigate the role of Pak1 in mediating Nf1 haploinsufficient phenotypes. 
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Figure 5- Loss of Pak1 reduces mast cell colony forming unit ability.  Low-density 
mononuclear cells (2x10
4
) were plated for the growth of CFU-Mast cell in 
methylcellulose supplemented with 20% FCS, 2.5ng/mL IL-3, and 10ng/mL of SCF.  
After 21 days of incubation, CFU-Mast were enumerated using indirect microscopy and 
normalized to the cellularity of both femurs, tibias, and iliac crests.  This total is 
expressed above as colony number/animal.  Each value represents the mean and the error 
bars represent the standard error of the mean of 3 independent experiments.  * indicates 
p<0.05 compared to WT control and ** indicates p<0.05 compared to Nf1
+/-
 control 
using Student’s unpaired T test. 
 47 
Loss of Pak1 does not affect expression of mast cell maturation markers 
 
To investigate whether genetic disruption of Pak1 does not influence mast cell 
development in intercrossed mast cells, low-density mononuclear bone marrow cells in 
the presence of serum and IL-3 were cultured for 4-5 weeks and expression of the c-kit 
receptor and FcεRI receptor was examined.  Fluorescence cytometry analysis of the F2 
progeny demonstrated equivalent expression of both c-kit and FcεRI receptors in all 
genotypes (Figure 6).  Further, the cells had typical cellular morphology and staining of 
cytoplasmic granules upon Alcian Blue/Saffranin-O staining (data not shown).  
Collectively, the fluorescence cytometry and histological data indicate that alterations in 
Pak1 expression do not influence c-kit expression or mast cell development in cells that 
are WT or haploinsufficient at the Nf1 locus. 
 
Hyperproliferation of Nf1
+/-
 bone marrow derived mast cells is dependent on a 
Pak1/MAPK pathway  
 
Given previous work demonstrating elevated Pak kinase activity in Nf1
+/-
 mast 
cells, as well as a pathological increase in Nf1
+/-
 mast cell proliferation through Ras-
MAPK signals 
60
, a combination of genetic and pharmacologic experiments were 
conducted to test the functional consequences of Pak1 loss on BMMCs.  Proliferation 
was assessed by Trypan blue exclusion at the time SCF was added (day 0) and after 72 h 
in culture.  As anticipated, Nf1
+/-
 BMMCs showed  greater proliferation in response to 
SCF compared with wild-type cells (Figure 7, black bars). Genetic disruption of Pak1  
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Figure 6- Loss of Pak1 does not affect expression of important mast cell maturation 
markers.  Mast cells were cultured for 4 weeks, and expression of c-kit and FcεRI were 
measured by incubation with anti-IgE followed by FITC-conjugated anti-mouse IgG, as 
well as PE-conjugated anti-c-kit antibodies.  Double positive cells (upper right quadrant) 
are mature mast cells, expressing both c-kit and FcεRI.  Data shown are representative of 
6 independent lines from each genotype. 
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resulted in a significant decrease in proliferation at 72 hours in Nf1
+/-
 cells (p<0.005), 
implicating Pak1 as a critical mediator of Nf1 haploinsufficient BMMC 
hyperproliferation.  Further, Pak1
-/-
 BMMCs had reduced proliferation (~60%) at 72 
hours compared to wild-type cells (p<0.05), suggesting that Pak1 is important for 
regulating proliferation in the setting of normal Ras activity as well.  
To link this phenotype to a particular MAPK pathway, concomitant proliferation 
experiments of cultured mast cells were performed in the presence or absence of 10µM 
PD98059, a selective inhibitor of Mek1 activity (Figure 7, white bars) or 10µM 
SB203580, a selective inhibitor of p38 MAPK (Figure 7, striped bars).  Addition of p38 
inhibitor SB203580 did not affect the proliferation of BMMCs of any genotype, 
indicating that p38 has little control over BMMC growth.  Conversely, inhibition of Mek 
by PD98059 caused significant decreases in mast cell proliferation in the context of 
normal Pak1 (~100% and 150% decreases for WT and Nf1
+/-
 BMMCs, respectively).  
Importantly, Mek inhibition did not significantly affect proliferation of Pak1 null cells, 
regardless of Nf1 genotype.  Collectively, these data imply that Pak1 interacts with the 
Mek/Erk MAPK pathway in Nf1
+/-
 mast cells to selectively regulate proliferation. 
 
Loss of Pak1 corrects MAPK hyperactivation in Nf1 haploinsufficient BMMCs 
 
 To establish the role of Pak1 signaling in the activation of the Ras-Raf-Mek-Erk 
signaling pathway and to identify the specific MAPK residues that are phosphorylated, 
BMMCs were stimulated with SCF and assayed for activated MAPK pathway members 
by using phospho-specific antibodies after Western blotting.  First, Erk1/2  
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Figure 7- Pak1 regulates the increased proliferation of Nf1
+/-
 mast cells in 
cooperation with Mek/Erk.  Mast cells were starved overnight in RPMI and plated in a 
24-well plate at 3x10
5
 per well in triplicate samples after treatment with DMSO (control; 
black bars), 10µM of selective p38 inhibitor SB203580 (striped bars), or 10µM of 
selective Mek1 inhibitor PD98059 (white bars).  Cells were then stimulated with 25ng of 
SCF for 72 hours, and viable cells were measured by trypan blue exclusion.  Results are 
expressed as percent of input number of cells at 72 hours post stimulation.  Each value 
represents the mean and the error bars represent the standard error of the mean of 6 
independent experiments.  * indicates p<0.05 compared to WT control, ** indicates 
p<0.05 compared to Nf1
+/-
 control, and # indicates p<0.05 compared to DMSO treated 
cells within a genotype using Student’s unpaired T test. 
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phosphorylation was measured.  Consistent with previous studies 
60
, Nf1
+/-
 BMMCs have 
a 2.5-fold increase in phosphorylated (activated) Erk1/2 (Figure 8).  Pak1
-/-
 mast cells had 
decreased Erk activation, and importantly genetic disruption of Pak1 fully corrects the 
hyperphosphorylation of Erk1/2 in Nf1
+/-
 mast cells to that of wild-type controls, which 
correlates with the correction in proliferation (Figure 7).  
  Frost et al. previously established that Pak1 directly activates Mek at serine 
residue 298 in NIH3T3 cells 
131
.  Immunoblotting of lysates from SCF stimulated Nf1
+/-
 
BMMCs revealed increased phosphorylation of Mek1 at this established target residue of 
direct Pak1 kinase activity compared to wild type controls (Figure 9).  Nf1
+/-
;Pak1
-/-
 mast 
cells showed greatly diminished phospho-Ser 298 Mek1 levels compared to Nf1
+/-
 cells 
(Figure 9).  In a similar manner, in Nf1
+/-
 BMMCs Mek phosphorylation at Ser 217/222, 
the site of Raf-1 dependent activation, is increased compared to wild type (Figure 10).  In 
Nf1
+/-
;Pak1
-/-
 mast cells stimulated with SCF, Mek Ser 217/222 activation is reduced 
compared to Nf1
+/-
 cells, close to wild type control levels (Figure 10).  Raf-1 has been 
described in multiple systems as a direct substrate of Pak at serine residue 338 
129,133,173
.  
These studies establish that Pak1, a downstream mediator of PI-3 K/Rac signaling, is 
biochemically linked to the classical Ras/Raf/Mek/Erk pathway in primary cells.  
Together with the proliferation data displayed in Figure 7, we establish a crucial role for 
Pak1 kinase activity in regulating the increased proliferation of Nf1
+/-
 BMMCs by 
relaying signals to the Mek/Erk pathway. 
 54 
 
 55 
Figure 8- Erk activation is reduced in cells that lack Pak1.  Mast cells were serum 
starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 minutes 
following stimulation.  100µg of protein were used for each time point.  Levels of active 
Erk1/2 were determined by immunoblotting using phospho-specific antibodies.  Levels of 
total Erk1/2 are shown as loading controls.  Western blot of the results is shown and is a 
representative of three independent experiments.  Each value represents the mean and the 
error bars represent the standard error of the mean of three independent experiments 
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Figure 9- Phosphorylation of Mek1 at Ser 298 is reduced in Pak1
-/-
 cells.  Mast cells 
were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 
minutes following stimulation.  100µg of protein were used for each time point.  Levels 
of active Mek1 were determined by immunoblotting using phospho-specific antibodies.  
Levels of total Mek1 are shown as loading controls.  Western blot of the results is shown 
and is a representative of three independent experiments.  Each value represents the mean 
and the error bars represent the standard error of the mean of 3 independent experiments. 
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Figure 10- Pak1 loss reduces phosphorylation of Ser217/221 on Mek1.  Mast cells 
were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 
minutes following stimulation.  100µg of protein were used for each time point.  Levels 
of active Mek1 were determined by immunoblotting using phospho-specific antibodies.  
Levels of total Mek1 are shown as loading controls.  Western blot of the results is shown 
and is a representative of three independent experiments.  Each value represents the mean 
and the error bars represent the standard error of the mean of three independent 
experiments. 
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A Pak1/p38 pathway regulates increased migration of Nf1
+/-
 mast cells 
 
 The recruitment of mast cells from the peripheral blood to sites of developing 
tumors is believed to be an early and required process in the formation of plexiform 
neurofibromas 
30,62,174
.  Nf1
+/-
 BMMCs have a PI3K- Rac-dependent gain-in-function in 
SCF mediated haptotaxis compared to wild type BMMCs 
62
.  Therefore, we questioned 
whether loss of Pak1 would be sufficient to correct the pathological increase in migration 
of Nf1
+/-
 BMMCs toward SCF.  To explore these questions transwells were coated with 
recombinant fibronectin fragment CH296 (Takara Biosystems) and migration assays 
were performed in response to 25ng/mL of SCF.  Following 4 hours of incubation in the 
transwells, the number of mast cells that had migrated to the bottom surface of the 
fibronectin-coated membrane was counted after staining the cells with crystal violet.  
BMMCs that were stimulated with media alone showed fewer than 5 cells per high power 
field had migrated to the lower side of the membrane (data not shown).  As expected, 
increased numbers of Nf1
+/-
 mast cells migrate toward SCF compared to wild type mast 
cells (Figure 11, black bars).  Also, loss of Pak1 causes a decrease in migration compared 
to wild type BMMCs (p<0.05).  Notably, Nf1
+/-
;Pak1
-/-
 BMMCs have decreases in the 
number of migrated mast cells compared to BMMCs haploinsufficient at the Nf1 locus, 
indicating that the increased migration in Nf1
+/-
 mast cells is Pak1 dependent.  
Previous studies have established that mast cells migrate in response to SCF in a 
p38-dependent manner 
175-177
.  To test if the gain-in-function phenotype for Nf1
+/-
 mast 
cell migration was the result of communication from Pak1 to p38, BMMCs were treated 
with 10µM of the selective inhibitor of p38 SB203580 (Figure 11, striped bars), 10µM of 
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the selective inhibitor of Mek1 PD98059 (Figure 11, white bars), or the vehicle only and 
stimulated as described above.  Interestingly, treatment of BMMCs with p38 inhibitor 
results in a significant decrease in migration of wild type and Nf1
+/-
 mast cells (by 28% 
and 41%, respectively), but does not further reduce migration of Pak1
-/-
 or Nf1
+/-
;Pak1
-/-
 
mast cells, implying that SCF stimulates Nf1
+/-
BMMC hyperactive migration through a 
Pak1/p38 pathway.  Treatment with the Mek1 inhibitor PD98059 did not affect the 
migration of BMMCs to SCF, as reported previously 
175
. 
 
Pak1 is required for the increase in p38 phosphorylation seen in Nf1 haploinsufficient 
mast cells 
 
 To establish a biochemical correlate to the functional results shown in Figure 9, 
which implicate a Pak1/p38 axis in mediating the increased migration of Nf1
+/-
 mast 
cells, BMMCs were stimulated with SCF and examined for levels of activated phospho-
p38 (R180/Y182).  Figure 12 shows that Nf1
+/-
 BMMCs have increased activated p38, 
consistent with the results of Figure 9.  Additionally, loss of Pak1 greatly diminishes 
phospho-p38 levels after SCF stimulation, providing biochemical evidence that SCF 
activates a Pak1/p38 pathway in mast cells.  This pathway is hyperactivated in Nf1
+/-
 
mast cells and leads to increased migration.  Therefore, molecular targeting of this 
pathway could potentially inhibit the recruitment of Nf1
+/-
 mast cells to sites of growing 
neurofibromas and delay or prevent tumor development. 
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Figure 11- Increased migration of Nf1
+/-
 mast cells is mediated through a Pak/p38 
pathway.  Mast cells were starved overnight in RPMI without serum and plated in the 
upper well of a transwell chamber at 1x10
5
 per well in triplicate samples after treatment 
with DMSO (control; black bars), 10µM of selective p38 inhibitor SB203580 (striped 
bars), or 10µM of selective Mek1 inhibitor PD98059 (white bars).  Cells were then 
stimulated with 25ng of SCF in the lower chamber for 4 hours, and mast cells that had 
migrated to the bottom surface of the CH296-coated membrane in response to SCF were 
counted after staining the cells with crystal violet.  Results are expressed as cells per 20x 
high power field.  Each value represents the mean and the error bars represent the 
standard error of the mean of 6 independent experiments.  * indicates p<0.05 compared to 
WT control, ** indicates p<0.05 compared to Nf1
+/-
 control, and # indicates p<0.05 
compared to DMSO treated cells within a genotype using Student’s unpaired T test.   
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Figure 12- Pak1
-/-
 Mast cells have diminished p38 activation.  Mast cells were serum 
starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 5 minutes 
following stimulation.  100µg of protein were used for each time point.  Levels of active 
p38 were determined by Western blotting using phospho-specific antibodies.  Level of 
total p38 is shown as a loading control.  Western blot of the results is shown and is a 
representative of three independent experiments.  Each value represents the mean and the 
error bars represent the standard error of the mean of three independent experiments. 
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Pak1 regulates F-actin content and organization in a p38-dependent manner 
 
 Actin polymerization at the cell front leads to the early extension of plasma 
membrane, which is necessary for cell migration 
178
.  c-Kit-mediated mast cell migration 
is highly dependent on alterations and activation of the actin cytoskeleton by Ras and PI-
3K 
164,179,180
.  Additionally, other groups have used overexpression systems to describe a 
role for Pak1 in the regulation of actin dynamics and migration in murine embryonic 
fibroblasts 
181
, murine bone marrow derived macrophages 
138
, and others.  Mast cells 
deficient in Rac2 (a direct activator of Pak1) have diminished actin cytoskeleton 
dependent functions 
164
.   Based on the established association of increases in F-actin 
content with the increases in migration seen in Nf1
+/-
 BMMCs 
62
, we hypothesized that 
the Pak1-dependent decrease in Nf1
+/-
 BMMC migration (Figure 11) stemmed from a 
disruption of the F-actin content and/or organization in these cells.    
To determine if Pak1 loss affects BMMC F-actin content, SCF-stimulated 
BMMCs were stained with phalloidin and analyzed using fluorescence cytometry and 
confocal microscopy.  Figure 13a-l shows representative confocal images of phalloidin 
and DAPI co-stained BMMCs.  At a single cell level, confocal images reveal that at 
baseline (Figure 11d) and after SCF stimulation (Figure 13e), Nf1
+/-
 BMMCs have 
increased phalloidin staining compared to wild type BMMCs (Figure 13a and 13b), while 
Pak1
-/-
 cells (Figure 13h) have decreased F-actin compared to wild type cells (Figure 
13b) after SCF stimulation.  Consistent with the functional migration data (Figure 11), 
the Nf1
+/-
;Pak1
-/-
 BMMCs (Figure 13k) have a reduction in F-actin levels compared to 
Nf1
+/-
 cells (Figure 13e) after SCF stimulation.  Figure 13m details a formal 
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quantification of the phalloidin intensity from six independent experiments utilizing 
FACS to quantitate F-actin content on SCF stimulated BMMCs.  
As shown in Figure 11, inhibition of p38 MAPK leads to decreases in wild type 
and Nf1
+/-
 mast cell migration, but does not affect the migration of Pak1
-/-
 cells.  To see if 
the observed differences in the cytoskeleton after SCF stimulation were linked to p38 
activity, we examined the F-actin content and organization of BMMCs that were 
incubated with 10µM SB203580 for 2h before stimulation.  As shown in Figure 13m, the 
total F-actin content in Nf1
+/-
 BMMCs was decreased after SB203580 treatment (striped 
bar).  Similar to the migration results in figure 11, inhibition of p38 MAPK did not 
significantly affect the total F-actin content of Nf1
+/-
;Pak1
-/-
 BMMC after SCF 
stimulation (Figure 13m); indicating that a hyperactive Pak1/p38 pathway regulates F-
actin formation in Nf1
+/-
 mast cells.  Confocal analysis of phalloidin stained BMMCs 
pretreated with SB203580 shows that the inhibition of p38 in wild type (Figure 13c) and 
Nf1
+/-
 mast cells (Figure 13f) disrupts the organization of F-actin to a pattern similar to 
that seen in BMMCs lacking Pak1 (Figures 13i and 13l). 
 
Disruption of Pak1 reduces granule release from Nf1
+/- 
mast cells 
 
The molecular processes that regulate the degranulation of preformed mediators in mast 
cells have implications in the development of neurofibromas, since Nf1
+/-
 mast cells have 
increased release of stored granules in vitro 
61
 as well as in NF1 patient samples 
9
. 
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Figure 13-  Pak1 and p38 cooperate to regulate activation and organization of the F-
actin cytoskeleton.  Mast cells were starved overnight in RPMI and plated in the upper 
well of a transwell chamber at 1x10
5
 per well in triplicate samples after treatment with 
DMSO or 10µM of selective p38 inhibitor SB203580.  Cells were then stimulated with 
25ng of SCF in the lower chamber for 30 minutes, and mast cells were removed from the 
upper chamber for phalloidin staining of the F-actin cytoskeleton.  A-L) Representative 
micrographs of phalloidin stained mast cells analyzed with the Zeiss UV LSM-510 
confocal microscope system.  Green=phalloidin stain, blue=DAPI nuclear stain.  Original 
magnification x400.  M) Fluorescence intensity of phalloidin stained mast cells, 
determined by fluorescence cytometry.  Data are expressed as fold increases over wild 
type levels, each value represents the mean and the error bars represent the standard error 
of the mean of 6 independent experiments.  * indicates p<0.05 compared to WT control, 
** indicates p<0.05 compared to Nf1
+/-
 control, and # indicates p<0.05 compared to 
DMSO treated cells within a genotype using Student’s unpaired T test.  
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To establish a role for Pak1 in regulating the gain-in-function of degranulation in Nf1
+/-
 
mast cells, we evaluated the release of β hexosminidase in response to SCF and IgE 
receptor stimulation.  Consistent with published reports 
61
, Nf1
+/-
 BMMCs have a 
significant increase (37%) in β hexosminidase release over wild type cells (Figure 14).  
However, Nf1
+/-
;Pak1
-/-
 BMMCs have a reduction in degranulation compared to Nf1
+/-
 
cells, back to the levels of wild type controls.  The Mek/Erk MAPK pathway has been 
implicated in regulating mast cell degranulation 
182
; however, treating mast cells with 
SB203580 to inhibit p38 does not affect mast cell mediator release 
183
.  In contrast to the 
proliferation data shown in Figure 7, treatment of Pak1 null BMMCs with PD98059 did 
reduce the amount of β hexosminidase released after IgE stimulation compared to DMSO 
treated controls (Figure 15), implying that for degranulation, the Pak1 and Mek/Erk 
pathways operate independently.  These findings support a role for Pak1 in mediating 
signals that control the hyperactive degranulation phenotype seen in mast cells 
haploinsufficient at Nf1. 
 
Loss of Pak1 does not significantly affect mast cell survival 
 
 Previous reports have established SCF as a survival factor for mast cells 
53
.  Given 
the finding that Nf1
+/-
 mast cells have increased, PI3-K dependent survival in response to 
SCF stimulation 
75
, and that Pak1 has been described as anti-apoptotic in multiple cellular 
lineages 
143,184,185
, we examined whether loss of Pak1 would affect the survival of SCF 
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Figure 14- Increased degranulation in Nf1
+/-
 mast cells is corrected by disruption of 
Pak1.  Mast cells were sensitized with anti-DNP IgE monoclonal antibody and assayed 
for degranulation by measuring the release of β hexosminidase release following 
treatment with 25ng/mL of SCF and 30ng/mL of DNP-HSA IgE receptor stimulation.  
Values express the mean percent difference of the wild type response and the error bars 
represent the standard error of the mean of 4 independent experiments.  * indicates p<.05 
compared to WT control, ** indicates p<.05 compared to Nf1
+/-
 control using Student’s 
unpaired T test. 
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Figure 15- Pak1 and Mek1/Erk operate in parallel pathways to regulate mast cell 
granule release.  Mast cells were sensitized with anti-DNP IgE monoclonal antibody and 
treated with 10µM of selective Mek1 inhibitor PD98059 for 2h.  Cells were assayed for 
degranulation by measuring the release of β hexosminidase release following treatment 
with 30ng/mL of DNP-HSA IgE receptor stimulation.  The percent release was calculated 
using the equation: (OD of supernatant/OD of pellet + OD of supernatant) x 100.  Values 
represent the mean from one representative experiment of three. 
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stimulated mast cells.  As expected, Nf1
+/-
 mast cells have reduced apoptosis 48 hours 
after SCF stimulation compared to wild type cells (Figure 16); however, genetic 
disruption of Pak1 did not significantly affect the survival of BMMCs, regardless of Nf1 
genotype.  These experiments demonstrate that, contrary to other cellular studies, Pak1 
does not regulate the survival responses induced by c-Kit stimulation in mast cells.      
 
Cutaneous expansion and degranulation of mast cells in Nf1 
+/-
 mice in response to SCF 
is Pak1-dependent 
 
In vivo mast cell expansion in response to local injection of SCF occurs secondary 
to local proliferation 
169
.  In order to determine if our in vitro findings are relevant in a 
more physiologic system, we examined cutaneous mast cell accumulation in vivo after 
local administration of SCF.  The progeny generated from the Nf1
+/-
 and Pak1
-/-
 genetic 
intercross were implanted with slow release microosmotic pumps to deliver 10 µg/kg/day 
of SCF or PBS (as a vehicle control) continuously.  Overlying skin sections were 
harvested 7 days later and stained with Giemsa to identify mast cells.  
 Representative histological sections from animals treated with SCF and stained 
with Giemsa are shown in Figure 17c-f.  Figure 17a shows quantitative results scoring the 
number of mast cells in the sections per mm
2
.  Pak1 null mice had a significant decrease 
in cutaneous mast cells compared to wild type mice after SCF delivery (Figure 17a).  
Nf1
+/-
 mice had a greater accumulation (>80% increase) of mast cells at the site of SCF 
infusion compared with wild type control mice (Figure 17a).  In keeping with the in vitro  
proliferation data (Figure 7), this excess expansion of cutaneous mast cells in Nf1
+/-
 mice 
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Figure 16- Loss of Pak1 does not affect the survival of wild type or Nf1
+/-
 mast cells.  
Bone marrow-derived mast cells were starved overnight in RPMI, plated in triplicate 
samples, and then stimulated with 25 ng/mL SCF.  Cells were assayed for apoptosis at 
each indicated time point by Annexin V/PI staining and analyzed by fluorescence 
cytometry.  Cells that were doubly positive for both Annexin V and PI were considered 
apoptotic.  Values represent the mean and the error bars represent the standard error of 
the mean 1 of 3 independent experiments performed in quadruplicate.  * indicates p<0.05 
compared to WT control using Student’s unpaired T test.  
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was corrected in Nf1
+/-
;Pak1
-/-
 mice.  SCF infusion into Nf1
+/-
 mice causes increased 
degranulation of local mast cells compared to wild type mice 
61
.  We reproduced this 
result (Figure 17b, and 17d, open arrows) and also found that loss of Pak1 corrects this 
phenotype by significantly reducing the percentage of degranulating mast cells in the skin 
of Nf1
+/-
;Pak1
-/-
 mice.  Our observations suggest that the biochemical mechanisms 
identified in vitro resulting from genetic disruption of Pak1 in mast cells are biologically 
operative in vivo. 
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Figure 17- Effect of genetic inactivation of Pak1 on accumulation of cutaneous Nf1
+/-
 
mast cells in response to local administration of SCF in vivo.  SCF was delivered in 
vivo via a microosmotic pump on the middorsum at 10ug/kg/day.  Skin sections at the site 
of SCF administration were fixed and stained with hematoxylin and eosin to assess 
routine histology along with Giemsa to identify mast cells.  A) Cutaneous mast cells were 
quantitated in a blinded fashion by counting 2mm
2
 sections, and B) The percentage of 
degranulating mast cells present per 2mm
2
 section was calculated.  Representative 
sections are displayed in C-F).  Resting mast cells in C-F) are marked with an , 
degranulating mast cells in C-F) are marked with an open arrow.  Values in A) and B) 
represent the mean of 3 independent experiments each using 3 mice per genotype and the 
error bars represent the standard error of the mean.  * indicates p<0.05 compared to WT 
control and ** indicates p<0.05 compared to Nf1
+/-
 control using Student’s unpaired T 
test. 
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ROLE OF Pak1 IN PLEXIFORM NEUROFIBROMA FORMATION 
 
Adoptive transfer of Nf1
+/-
;Pak1
-/-
 bone marrow into Schwann cell nullizygous recipients  
 
 Based on the results above which identified Pak1 as a regulator of gains-in-
function associated with Nf1 haploinsufficiency in mast cells, we hypothesized that Pak1 
signaling in the hematopoietic compartment of the neurofibroma microenvironment could 
contribute to tumor formation in vivo.  To test this hypothesis, we transferred either Nf1
+/-
  
(as a positive control) or Nf1
+/-
;Pak1
-/-
 bone marrow into mice with conditionally ablated 
Nf1 alleles in the Schwann cell lineage.  Two experimental groups of recipient mice were 
used.  First, we used Krox20Cre;Nf1
flox/flox 
mice, which are functionally WT in all non-
Schwann cell lineages and do not spontaneously develop neurofibromas.  Recent work 
has shown that transplantation of Nf1
+/- 
bone marrow into Krox20Cre;Nf1
flox/flox
 mice is 
sufficient to stimulate neurofibroma development 
64
, therefore we hypothesized that 
transfer of Nf1
+/-
;Pak1
-/- 
 bone marrow would not be permissive to allow tumor 
formation. Additionally, we used Krox20Cre;Nf1
flox/- 
as recipients, which contain a 
germline disruption of one copy of  Nf1 and a floxed allele susceptible to recombination 
in the Schwann cell lineage.  Krox20Cre;Nf1
flox/-
 consistently develop plexiform 
neurofibromas around the spinal nerve roots within 8 months of life 
30,64
.  We predicted 
that Krox20Cre;Nf1
flox/- 
mice reconstituted with Nf1
+/-
;Pak1
-/- 
 bone marrow would 
prevent or delay the formation of tumors in these mice.  A schematic of the experimental 
design is outlined in Figure 18. 
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Figure 18- Neurofibroma formation experimental design.  Schematic showing the 
genotypes of recipient mice, the genotypes of adoptively transferred cells following 
ionizing radiation of the recipients, and measurements obtained following transplantation.   
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Krox20Cre;Nf1
flox/flox
 mice reconstituted with Nf1
+/-
;Pak1
-/- 
 bone marrow develop 
plexiform neurofibromas 
 
 Following 1100 Rads of ionizing radiation, 5x10
6
 whole bone marrow cells from 
Nf1
+/-
 mice or Nf1
+/-
;Pak1
-/-
 mice were transplanted into Krox20Cre;Nf1
flox/flox
 mice.  
These mice were followed after transplant for 12-15 months before they were sacrificed 
and investigated for tumor formation along the spinal nerve roots.  There was no 
difference in post-transplant survival between the recipients of Nf1
+/-
 marrow or Nf1
+/-
;Pak1
-/-
 marrow (over 85% survival in both groups at 12 months).  Necropsy of the spinal 
nerves showed enlargement of dorsal root ganglia in both recipients of Nf1
+/-
 marrow as 
well as recipients of Nf1
+/-
;Pak1
-/-
 marrow.  Volumetric analysis of these dorsal root 
ganglia showed no significant changes in the volume of the dorsal root ganglia of the 
sciatic nerve (which is a common location for neurofibromas in Krox20Cre;Nf1
flox/-
 mice) 
between recipients of Nf1
+/-
 marrow versus recipients of Nf1
+/-
;Pak1
-/-
 marrow (Figure 
19). 
 Unexpectedly, histological examination of sections of dorsal root ganglia and 
proximal peripheral nerves from 100% of recipients of both of Nf1
+/-
 bone marrow as 
well as 100% of recipients of Nf1
+/-
;Pak1
-/-
  bone marrow revealed the presence of 
classical pathologic features of plexiform neurofibromas.  These include disruptions of 
nerve root architecture and Schwann cells (Figure 20), increased angiogenesis and blood 
vessel presence in the nerve (Figure 20, red arrows), as well as substantial collagen 
deposition (Figure 21).  Interestingly, while both recipients of both of Nf1
+/-
 bone marrow 
and recipients of Nf1
+/-
;Pak1
-/-
  bone marrow have increases in the number of infiltrating  
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Figure 19- Krox20Cre;Nf1
flox/flox
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 mice develop 
enlarged sciatic nerve dorsal root ganglia.  Krox20Cre;Nf1
flox/flox
 mice were sacrificed 
12-15 months after transplantation with Nf1
+/-
 or Nf1
+/-
;Pak1
-/-
 bone marrow and the 
spinal cord and nerve roots of each animal were dissected.  The dorsal root ganglia 
dimensions were obtained by measurement with calipers and volume was determined by 
using the formula (0.52 x (width)
2
 x (length)) to approximate spheroidal volume.  Values 
represent the mean of 15 recipients of Nf1
+/-
  marrow and 11 recipients of Nf1
+/-
;Pak1
-/-
  
marrow, and error bars represent the standard error of the mean.  No significant 
difference between the means of the two genotypes was found using Student’s unpaired T 
test. 
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Figure 20- Krox20Cre;Nf1
flox/flox
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
develop histologically identifiable plexiform neurofibromas.  Representative 
hematoxylin and eosin (H&E) stained sections of dorsal root ganglia and proximal 
peripheral nerves from Krox20Cre;Nf1
flox/flox 
 mice transplanted with either Nf1
+/-
  
marrow or Nf1
+/-
;Pak1
-/-
 marrow.  Blood vessels are identified by red arrows.  Genotypes 
of donor bone marrow are indicated, along with a representative section of normal nerve 
root.  Photos were taken with a light microscope under 200x magnification. 
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Figure 21- Krox20Cre;Nf1
flox/flox
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
have collagen deposition characteristic of plexiform neurofibromas.  Representative 
sections of dorsal root ganglia and proximal peripheral nerves from Krox20Cre;Nf1
flox/flox 
 
mice transplanted with either Nf1
+/-
  marrow or Nf1
+/-
;Pak1
-/-
 marrow were stained with 
Masson’s trichrome to identify collagen content..  Collagen is identified by bright blue 
staining.  Genotypes of donor bone marrow are indicated, along with a representative 
section of normal nerve root.  Photos were taken with a light microscope under 200x 
magnification. 
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Figure 22- Krox20Cre;Nf1
flox/flox
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
have reduced mast cell numbers present in plexiform neurofibromas.  A) 
Representative sections of dorsal root ganglia and proximal peripheral nerves from 
Krox20Cre;Nf1
flox/flox 
 mice transplanted with either Nf1
+/-
  marrow or Nf1
+/-
;Pak1
-/-
 
marrow were stained with Alcian blue to identify mast cell numbers.  Mast cells are 
identified by red arrows.  Genotypes of donor bone marrow are indicated, along with a 
representative section of normal nerve root.  Photos were taken with a light microscope 
under 200x magnification.  B) Number of mast cells present in Alcian blue sections from 
8 animals per genotype were quantitated by counting mast cells per high power field.  
Values represent the mean and the error bars represent the standard error of the mean.  * 
indicates p<0.05 compared to Nf1
+/-
 recipients using Student’s unpaired T test. 
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mast cells to the dorsal root ganglia (Figure 22a, red arrows), recipients of Nf1
+/-
;Pak1
-/-
  
bone marrow have a significant decrease (~38%) in the number of mast cells compared to 
recipients of Nf1
+/-
  bone marrow (Figure 22b).  Despite this decrease in mast cell 
number, reconstitution of Krox20Cre;Nf1
flox/flox 
mice with Nf1
+/-
;Pak1
-/-
 bone marrow 
lead to similar outcomes in terms of neurofibroma development and structure as 
Krox20Cre;Nf1
flox/flox 
mice with Nf1
+/-
  bone marrow, indicating that loss of Pak1 in the 
tumor microenvironment still permitted the hematopoietic compartment to induce 
neurofibroma formation. 
 
Krox20Cre;Nf1
flox/-
 mice reconstituted with Nf1
+/-
;Pak1
-/- 
 bone marrow develop 
plexiform neurofibromas 
 
 In a similar manner, irradiated Krox20Cre;Nf1
flox/-
 mice received bone marrow 
from Nf1
+/-
 mice or Nf1
+/-
;Pak1
-/-
 mice and were followed after transplant for 12-15 
months before they were sacrificed and investigated for tumor formation along the spinal 
nerve roots.  As with Krox20Cre;Nf1
flox/flox
 recipients, Krox20Cre;Nf1
flox/-
 mice had 
similar post-transplant mortality (over 85% survival in both groups at 12 months) 
regardless of the genotype of transplanted marrow.  Necropsy of the spinal nerves 
showed enlargement of dorsal root ganglia in both recipients of Nf1
+/-
 marrow as well as 
recipients of Nf1
+/-
;Pak1
-/-
 marrow.  Volumetric analysis of these dorsal root ganglia 
showed no significant changes in the volume of the dorsal root ganglia of the sciatic 
nerve between recipients of Nf1
+/-
 marrow versus recipients of Nf1
+/-
;Pak1
-/-
 marrow 
(Figure 23). 
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 Pathologic analysis demonstrated the presence of plexiform neurofibromas in 
100% of Krox20Cre;Nf1
flox/-
 mice transplanted with Nf1
+/-
;Pak1
-/-
 bone marrow.  
Recipients of Nf1
+/-
;Pak1
-/-
 bone marrow had very similar histological features as 
recipients of Nf1
+/-
 bone marrow, including disorganized cellular architecture (Figure 24), 
increased numbers of blood vessels (Figure 24, red arrows), and large deposits of 
collagen in the ECM (Figure 25).  In contrast to the results shown in Figure 22b which 
describe a reduction in the number of mast cells present in neurofibromas found in 
Krox20Cre;Nf1
flox/flox
 mice transplanted with Nf1
+/-
;Pak1
-/-
 bone marrow, 
Krox20Cre;Nf1
flox/-
 mice transplanted with Nf1
+/-
;Pak1
-/-
 bone marrow have equal 
numbers of mast cells as Krox20Cre;Nf1
flox/-
 mice transplanted with Nf1
+/-
 bone marrow 
(Figure 26).  These experiments using adoptive transfer of bone marrow into 
Krox20Cre;Nf1
flox/-
 mice demonstrate that disruption of Pak1 in the hematopoietic system 
is not sufficient to counteract the neurofibroma stimulating phenotype of the Nf1 
haploinsufficient microenvironment. 
 
Genetic disruption of Pak1 in Krox20Cre;Nf1
flox/-
 mice does not prevent neurofibroma 
formation 
 
 Adoptive transfer of Nf1
+/-
;Pak1
-/-
 bone marrow into Krox20Cre;Nf1
flox/flox
 or  
Krox20Cre;Nf1
flox/-
 mice resulted in the development of neurofibromas similar to mice 
transplanted with Nf1
+/- 
 bone marrow.  Therefore, we were interested in the tumor 
forming ability of conditionally disrupted Nf1 mice that lacked Pak1 in all lineages, not 
just the hematopoietic compartment.  Genetic intercross of Krox20Cre;Nf1
flox/- 
mice with  
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Figure 23- Krox20Cre;Nf1
flox/-
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 mice develop 
enlarged sciatic nerve dorsal root ganglia.  Krox20Cre;Nf1
flox/-
 mice were sacrificed 
12-15 months after transplantation with Nf1
+/-
 or Nf1
+/-
;Pak1
-/-
 bone marrow and the 
spinal cord and nerve roots of each animal were dissected.  The dorsal root ganglia 
dimensions were obtained by measurement with calipers and volume was determined by 
using the formula (0.52 x (width)
2
 x (length)) to approximate spheroidal volume.  Values 
represent the mean of 6 recipients of Nf1
+/-
  marrow and 4 recipients of Nf1
+/-
;Pak1
-/-
  
marrow, and error bars represent the standard error of the mean.  No significant 
difference between the means of the two genotypes was found using Student’s unpaired T 
test. 
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Figure 24- Krox20Cre;Nf1
flox/-
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
develop histologically identifiable plexiform neurofibromas.  Representative 
hematoxylin and eosin (H&E) stained sections of dorsal root ganglia and proximal 
peripheral nerves from Krox20Cre;Nf1
flox/- 
 mice transplanted with either Nf1
+/-
  marrow 
or Nf1
+/-
;Pak1
-/-
 marrow.  Blood vessels are identified by red arrows.  Genotypes of 
donor bone marrow are indicated, along with a representative section of normal nerve 
root.  Photos were taken with a light microscope under 200x magnification. 
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Figure 25- Krox20Cre;Nf1
flox/-
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
have collagen deposition characteristic of plexiform neurofibromas.  Representative 
sections of dorsal root ganglia and proximal peripheral nerves from Krox20Cre;Nf1
flox/- 
 
mice transplanted with either Nf1
+/-
  marrow or Nf1
+/-
;Pak1
-/-
 marrow were stained with 
Masson’s trichrome to identify collagen content.  Collagen is identified by bright blue 
staining.  Genotypes of donor bone marrow are indicated, along with a representative 
section of normal nerve root.  Photos were taken with a light microscope under 200x 
magnification. 
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Figure 26- Krox20Cre;Nf1
flox/-
 mice reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow 
have plexiform neurofibromas infiltrated with numerous inflammatory mast cells.  
A) Representative sections of dorsal root ganglia and proximal peripheral nerves from 
Krox20Cre;Nf1
flox/- 
 mice transplanted with either Nf1
+/-
  marrow or Nf1
+/-
;Pak1
-/-
 marrow 
were stained with Alcian blue to identify mast cell numbers.  Mast cells are identified by 
red arrows.  Genotypes of donor bone marrow are indicated, along with a representative 
section of normal nerve root.  Photos were taken with a light microscope under 200x 
magnification.  B) Number of mast cells present in Alcian blue sections from 4 animals 
per genotype were quantitated by counting mast cells per high power field.  Values 
represent the mean and the error bars represent the standard error of the mean.  No 
significant difference between the means of the two genotypes was found using Student’s 
unpaired T test. 
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Nf1
+/-;
Pak1
-/-
 mice generated Krox20Cre;Nf1
flox/-
;Pak1
-/-
 progeny in the F2 generation.  
These Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice were followed for 12-15 months with 
Krox20Cre;Nf1
flox/-
 mice as positive controls to assess plexiform neurofibroma 
development.  After 12 months, the survival of Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice was 
equivalent to the Krox20Cre;Nf1
flox/-
 mice (~50% survival for both genotypes).   
 Dissection of the spinal cord and proximal spinal nerves revealed enlargement of 
the dorsal root ganglia and spinal nerve roots in Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice (Figure 
27).  Volumetric analysis of these dorsal root ganglia showed no significant changes in 
the volume of the dorsal root ganglia of the sciatic nerve between Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice and Krox20Cre;Nf1
flox/-
 mice (Figure 27). 
 Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice displayed histological signs of neurofibroma 
formation as evidenced by disruptions in nerve root architecture (Figure 28), increased 
angiogenesis (Figure 28, red arrows), high amounts of collagen deposition (Figure 29), 
and the infiltration of mast cells (Figure 30a, red arrows).  No significant differences in 
mast cell numbers within the neurofibroma were found (Figure 30b).   
 Table 1 details the results of plexiform neurofibroma experiments performed by 
our group and colleagues and lists the genotypes of the relevant cell lineages in each set 
of trials.  The results of the experiments described in detail within this study demonstrate 
that genetic disruption of Pak1 in the Krox20Cre;Nf1
flox/-
 plexiform neurofibroma tumor 
model is insufficient for preventing tumor formation in vivo.
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Figure 27- Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice develop enlarged sciatic nerve dorsal root 
ganglia. Krox20Cre;Nf1
flox/-
;Pak1
-/-
  and Krox20Cre;Nf1
flox/-
 mice were sacrificed after 
12-15 months and the spinal cord and nerve roots of each animal were dissected.  The 
dorsal root ganglia dimensions were obtained by measurement with calipers and volume 
was determined by using the formula (0.52 x (width)
2
 x (length)) to approximate 
spheroidal volume.  Values represent the mean of 15 animals per genotype and error bars 
represent the standard error of the mean.  No significant difference between the means of 
the two genotypes was found using Student’s unpaired T test. 
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Figure 28- Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice develop histologically identifiable 
plexiform neurofibromas.  Representative hematoxylin and eosin (H&E) stained 
sections of dorsal root ganglia and proximal peripheral nerves from Krox20Cre;Nf1
flox/-
;Pak1
-/-
  and Krox20Cre;Nf1
flox/-
 mice.  Blood vessels are identified by red arrows.  
Genotypes of each group are indicated, along with a representative section of normal 
nerve root.  Photos were taken with a light microscope under 200x magnification. 
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Figure 29- Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice have collagen deposition characteristic of 
plexiform neurofibromas.  Representative sections of dorsal root ganglia and proximal 
peripheral nerves from Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice  and Krox20Cre;Nf1
flox/-
 mice 
were stained with Masson’s trichrome to identify collagen content.  Collagen is identified 
by bright blue staining.  Genotypes of each group are indicated, along with a 
representative section of normal nerve root.  Photos were taken with a light microscope 
under 200x magnification. 
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Figure 30- Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice have plexiform neurofibromas infiltrated 
with numerous inflammatory mast cells.  A) Representative sections of dorsal root 
ganglia and proximal peripheral nerves from Krox20Cre;Nf1
flox/-
;Pak1
-/- 
mice  and 
Krox20Cre;Nf1
flox/-
 mice were stained with Alcian blue to identify mast cell numbers.   
Mast cells are identified by red arrows.  Genotypes of each group are indicated, along 
with a representative section of normal nerve root.  Photos were taken with a light 
microscope under 200x magnification.  B) Number of mast cells present in Alcian blue 
sections from 4 animals per genotype were quantitated by counting mast cells per high 
power field.  Values represent the mean and the error bars represent the standard error of 
the mean.  No significant difference between the means of the two genotypes was found 
using Student’s unpaired T test. 
 118 
 
 119 
Table 1- Results of plexiform neurofibroma formation studies using the 
Krox20Cre;Nf1
flox
 conditional knockout animal model. 
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ROLE OF Pak1 IN MEDIATING PDGF-BB AND TGF-β DEPEDENT 
FUNCTIONS IN FIBROBLASTS 
 
PDGF-BB mediated fibroblast proliferation is Pak1 dependent  
 
 Work by Rhee and Grinnell demonstrated that human fibroblasts treated with 
siRNA to Pak1 had disruptions in their ability to form cell ruffles and dendritic 
extensions of the cytoplasm in response to PDGF-BB 
186
.  Since fibroblast activity and 
collagen secretion is important to the pathogenesis of plexiform neurofibromas, we 
examined whether a role for Pak1 existed in regulating various PDGF-BB dependent 
functions.  First, we stimulated wild type and Pak1
-/-
 fibroblasts with 50ng/mL of PDGF-
BB for 36 hours and carried out 
[3H]
thymidine incorporation assays to evaluate 
proliferation.  Figure 31 shows that disruption of Pak1 causes significant decreases in 
fibroblast proliferation.  PDGF-BB activation of Erk is critical to its role in stimulating 
proliferation 
187
, and we and others have shown that Pak1 is necessary for activation of 
Erk.   Therefore, we stimulated fibroblasts with 50ng/mL of PDGF-BB and assayed for 
activated Erk1/2 by using phospho-specific antibodies after Western blotting.  Pak1
-/-
 
fibroblasts consistently display decreased activation of Erk1/2 (Figure 32) suggesting a 
molecular mechanism for the findings of Figure 31. 
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Figure 31- Pak1
-/-
 fibroblasts have reduced proliferation following PDGF-BB 
stimulation.  Approximately 2x10
4
 fibroblasts were plated and starved for 24 hours 
before stimulation with 50ng/mL of PDGF-BB.  After 24 hours of stimulation at 37
o
, 
[3H]
thymidine was added for 6 hours and its incorporation was measured.  Values 
represent the mean of 3 independent experiments performed with six replicates each and 
the error bars represent the standard error of the mean.  * indicates p<0.05 compared to 
WT control using Student’s unpaired T test. 
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Figure 32- Loss of Pak1 reduces Erk activation following PDGF-BB stimulation in 
fibroblasts.  Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of 
PDGF-BB, and cell lysates isolated at time points indicated following stimulation.  
100µg of protein were used for each time point.  Levels of active Erk1/2 were determined 
by immunoblotting using phospho-specific antibodies.  Levels of total Erk1/2 are shown 
as loading controls.  Western blot of the results is shown and is a representative of three 
independent experiments. 
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Loss of Pak1 does not affect TGF-β induced fibroblast proliferation 
 
 Similar to PDGF-BB, TGF-β is a growth factor that stimulates multiple responses 
from fibroblasts.  TGF-β is a potent modulator of fibroblast proliferation and is known to 
be released at high concentrations by mast cells in the neurofibroma        
microenvironment 
71
.  Therefore, we examined whether Pak1 deficient fibroblasts had 
reduced proliferation after TGF-β stimulation.  Unlike stimulation with PDGF-BB, Pak1-
/- 
fibroblasts had no statistically significant changes in 
[3H]
thymidine incorporation after 
36 hours of incubation with 2ng/mL TGF-β (Figure 33).  This was accompanied by 
immunoblots detailing no change in activated Erk levels after TGF-β stimulation (Figure 
34).  Together, these results indicate that Pak1 is important for MAPK activation and 
proliferation of fibroblast after stimulation with PDGF-BB, but not TGF-β. 
 
Pak1 deficient fibroblasts have reduced migration following PDGF-BB stimulation 
 
 Early work on Pak1 in fibroblast cell lines indicated that Pak1 regulated actin 
organization and content following PDGF-BB stimulation 
124
.  More recent work has 
implied a role for Pak1 in regulating fibroblast migration in response to PDGF-BB 
186
.  
Based on these reports, we used primary Pak1
-/-
 fibroblasts to investigate how loss of 
Pak1 could affect PDGF-BB ability to induce migration and signal to the cytoskeleton.  
We used a wound-healing assay as an assessment of fibroblast migration following 
PDGF-BB treatment.  These experiments revealed a 2.5 fold increase in the migration of 
wild type fibroblasts as compared to Pak1
-/-
 cells (Figure 35). Representative 
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Figure 33- Loss of Pak1 does not significantly affect fibroblast proliferation 
following TGF-β stimulation.  Approximately 2x104 fibroblasts were plated and starved 
for 24 hours before stimulation with 2ng/mL of TGF-β.  After 24 hours of stimulation at 
37
o
, 
[3H]
thymidine was added for 6 hours and its incorporation was measured.  Values 
represent the mean of 3 independent experiments performed with six replicates each and 
the error bars represent the standard error of the mean.  No significant difference between 
the means of the two genotypes was found using Student’s unpaired T test. 
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Figure 34- Pak1
-/-
 fibroblasts have normal Erk activation after stimulation with 
TGF-β.  Fibroblasts were serum starved for 48 hours, stimulated with 2ng/mL of TGF-β, 
and cell lysates isolated at time points indicated following stimulation.  100µg of protein 
were used for each time point.  Levels of active Erk1/2 were determined by 
immunoblotting using phospho-specific antibodies.  Levels of total Erk1/2 are shown as 
loading controls.  Western blot of the results is shown and is a representative of three 
independent experiments. 
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photomicrographs of crystal violet stained wild type or Pak1
-/-
 fibroblasts that migrated 
into the wound in response to 18 hours of 50ng/mL PDGF-BB stimulation is shown in 
Figure 35. 
 
Disruptions of PDGF-BB mediated activation of the actin cytoskeleton and associated 
signaling networks are found in Pak1
-/-
 fibroblasts 
 
 Since we found Pak1
-/-
 fibroblasts to have reduced migration, and numerous 
reports describe Pak1 altering migration via the actin cytoskeleton 
101
, we investigated the 
activation of important downstream targets of Pak1 that regulate actin, including filamin 
A and cofilin.  First activation of filamin A was assessed.  Phosphorylation of filamin A 
at Ser2152 increases its ability to bind actin and reorganize the cytoskeleton 
126
.  We 
show that Pak1
-/-
 fibroblasts have decreased Ser2152 phosphorylation of filamin A after 
PDGF-BB stimulation (Figure 36).  Additionally, we examined the phosphorylation 
status of cofilin, an actin binding protein that, in its dephosphorylated state, leads to 
depolymerization of actin filaments.  Figure 37 shows that fibroblasts that lack Pak1 have 
decreased phospho-cofilin, indicating an increase in the actin disrupting ability of cofilin.  
Taken together, these results implied that the actin cytoskeleton was likely to be 
deregulated in Pak1
-/-
 fibroblasts.  To visualize the actin networks in PDGF-BB 
stimulated fibroblasts, cells grown on coverslips were used in wound healing assays and 
after 5 hours were stained with phalloidin to stain filamentous actin.  Representative 
micrographs taken from confocal analysis of these cells indicates that wild type 
fibroblasts stimulated with PDGF-BB have increased invasion of the wound compared 
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Figure 35- Pak1
-/-
 fibroblasts have diminished migration in response to PDGF-BB.  
Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette 
tip prior to stimulation with 50ng/mL of PDGF-BB.  After 12 hours incubation, the cells 
were fixed and stained with crystal violet solution and the number of cells that invaded 
the would were counted.  Photos were taken with a light microscope under 100x 
magnification.  Values represent the mean of 3 independent experiments performed in 
triplicate and the error bars represent the standard error of the mean.  * indicates p<0.05 
compared to WT control using Student’s unpaired T test. 
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Figure 36- Pak1 loss reduces activation of Filamin-A after PDGF-BB stimulation.  
Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of PDGF-BB, and 
cell lysates isolated at time points indicated following stimulation.  100µg of protein were 
used for each time point.  Levels of active Filamin-A were determined by 
immunoblotting using phospho-specific antibodies.  Levels of total β-actin are shown as 
loading controls.  Western blot of the results is shown and is a representative of three 
independent experiments. 
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Figure 37- Pak1 loss results in reduced inactivation of Cofilin following stimulation 
by PDGF-BB.  Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of 
PDGF-BB, and cell lysates isolated at time points indicated following stimulation.  
100µg of protein were used for each time point.  Levels of inactive cofilin were 
determined by immunoblotting using phospho-specific antibodies.  Levels of total cofilin 
are shown as loading controls.  Western blot of the results is shown and is a 
representative of three independent experiments. 
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Figure 38- Pak1
-/-
 fibroblasts have disruptions in the organization of the F-actin 
cytoskeleton after PDGF-BB stimulation.  Quiescent, mitotically inactivated 
monolayers of fibroblasts were scratched with a pipette tip prior to stimulation with 
50ng/mL of PDGF-BB.  After 5 hours incubation, the cells were fixed and stained with 
phalloidin and DAPI to visualize F-actin and nuclei, respectively.  Low power 
micrographs in A-D) were taken with the Zeiss UV LSM-510 confocal microscope 
system.  Green=phalloidin stain, blue=DAPI nuclear stain.  Original magnification x100.  
E-F) are high power views of similar fields of cells.  Original magnification x400.   
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to Pak1
-/-
 cells (Figure 38b and 38d).  Furthermore, wild type fibroblasts have 
qualitatively more F-actin in the cytoplasm of cells invading the wound than the Pak
-/-
 
cells, as evidenced by the high power micrographs shown in Figure 38 f and h, 
respectively.  As a group, the results of these experiments indicate that loss of Pak1 
results in decreased phosphorylation of filamin A and cofilin, leading to disruptions of 
the actin cytoskeleton that impair normal migration in response to PDGF-BB. 
 
Loss of Pak1 decreases TGF-β dependent fibroblast migration   
 
 TGF-β mediated wound invasion is an important step in many pathological 
processes, including tumor formation 
69
.  To determine if Pak1 signaling downstream of 
TGF-β was involved in the regulation of fibroblast migration, wound healing assays 
using 2ng/mL of TGF-β for stimulation were performed.  After 24 hours of stimulation, 
the Pak1
-/-
 fibroblasts displayed a significant reduction in wound invasion compared to 
wild type (Figure 39).  Similar to the results found with PDGF-BB, Pak1
-/- 
fibroblasts 
have impaired migration ability.      
 
TGF-β stimulated fibroblasts have decreased activation of filamin A and disrupted actin 
cytoskeletal networks 
 
 Since Pak1
-/-
 fibroblasts had comparable deficits in migration in response to both 
PDGF-BB and TGF-β stimulation, we were interested if TGF-β induced similar 
disruption of actin signaling networks found in PDGF-BB stimulated Pak1 null cells 
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(Figures 36-38).  Analogous to PDGF-BB stimulated fibroblasts, loss of Pak1 results in 
impaired phosphorylation of filamin A at Ser 2152 (Figure 40).  Interestingly, in response 
to TGF-β, cofilin phosphorylation remained intact in Pak1-/- cells (Figure 41).  However, 
confocal analysis of phalloidin stained fibroblasts stimulated with 2ng/mL of TGF-β for 5 
hours showed decreased amounts of higher level actin bundle organization in wound 
invading Pak1
-/-
 cells (Figure 42 h, red arrow) compared to wild type cells.  These 
experiments point toward a potential Pak1 mediated signaling pathway where Filamin A, 
but not cofilin, is an important regulator of TGF-β mediated actin organization and 
fibroblast migration. 
 
Pak1
-/-
 fibroblasts have reduced collagen synthesis in vitro in response to TGF-β 
 
 Interstitial collagen secretion is one of the primary functions of fibroblasts and is 
associated with numerous disease processes, including plexiform neurofibroma    
formation 
71,188
.  Since both PDGF-BB and TGF-β are known profibrotic cytokines and 
are released in large amounts by mast cells at the site of plexiform neurofibroma 
formation, we investigated if loss of Pak1
-/-
 would alter the ability of fibroblasts to 
secrete collagen following stimulation with either growth factor.  Using the Sircol 
collagen assay system, we evaluated the supernatants from confluent cultures of 
fibroblasts stimulated for 48 hours with either 50ng/mL PDGF-BB or 2ng/mL TGF-β for 
collagen production.  Although PDGF-BB stimulated Pak1
-/-
 fibroblasts had statistically 
similar amounts of collagen secretion as wild type cells; TGF-β stimulation led to 
decreased collagen production in Pak1 null cells (Figure 43).  This experiment supports a 
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Figure 39- Pak1
-/-
 fibroblasts have diminished migration in response to TGF-β.  
Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette 
tip prior to stimulation with 2ng/mL of TGF-β.  After 24 hours incubation, the cells were 
fixed and stained with crystal violet solution and the number of cells that invaded the 
would were counted.  Photos were taken with a light microscope under 100x 
magnification.  Values represent the mean of 3 independent experiments performed in 
triplicate and the error bars represent the standard error of the mean.  * indicates p<0.05 
compared to WT control using Student’s unpaired T test. 
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Figure 40- Pak1 loss reduces activation of Filamin-A after TGF-β stimulation.  
Fibroblasts were serum starved for 48 hours, stimulated with 2ng/mL of TGF-β, and cell 
lysates isolated at time points indicated following stimulation.  100µg of protein were 
used for each time point.  Levels of active Filamin-A were determined by 
immunoblotting using phospho-specific antibodies.  Levels of total β-actin are shown as 
loading controls.  Western blot of the results is shown and is a representative of three 
independent experiments. 
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Figure 41- Pak1 loss does not significantly affect phosphorylation of Cofilin 
following stimulation by TGF-β.  Fibroblasts were serum starved for 48 hours, 
stimulated with 50ng/mL of TGF-β, and cell lysates isolated at time points indicated 
following stimulation.  100µg of protein were used for each time point.  Levels of 
inactive cofilin were determined by immunoblotting using phospho-specific antibodies.  
Levels of β-actin are shown as loading controls.  Western blot of the results is shown and 
is a representative of three independent experiments. 
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Figure 42- Pak1
-/-
 fibroblasts have disruptions in the organization of the F-actin 
cytoskeleton after TGF-β stimulation.  Quiescent, mitotically inactivated monolayers 
of fibroblasts were scratched with a pipette tip prior to stimulation with 2ng/mL of    
TGF-β.  After 5 hours incubation, the cells were fixed and stained with phalloidin and 
DAPI to visualize F-actin and nuclei, respectively.  Low power micrographs in A-D) 
were taken with the Zeiss UV LSM-510 confocal microscope system.  Green=phalloidin 
stain, blue=DAPI nuclear stain.  Original magnification x100.  E-F) are high power views 
of similar fields of cells.  Original magnification x400.   
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Figure 43- Loss of Pak1 reduces collagen production after TGF-β stimulation.  
Confluent monolayers of fibroblasts were stimulated with 50ng/mL of PDGF-BB or 
2ng/mL of TGF-β for 48 hours at 37o.  Collagen levels in the supernatant were measured 
using the Sircol dye reagent and OD levels assessed using a microplate reader.  Values 
represent the mean of 3 independent experiments performed in triplicate and the error 
bars represent the standard error of the mean.  * indicates p<0.05 compared to WT using 
Student’s unpaired T test. 
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role for Pak1 in regulating collagen production from fibroblasts in response to TGF-β. 
 
Reduced survival of Pak1 null fibroblasts in response to TGF-β and PDGF-BB    
 
 Due to the fact that Pak1 is associated with anti-apoptotic actions in other cell 
types 
143,184,185
, we were interested to see if genetic disruption of Pak1 in fibroblasts 
would affect their survival in response to PDGF-BB or TGF-β.  Confluent fibroblasts 
were serum starved for 24 hours before being treated with 10% fetal calf serum, 50ng/mL 
PDGF-BB, or 2ng/mL TGF-β.  Cells were fixed and subjected to a TUNEL assay and 
analyzed for survival using fluorescence cytometry.  Cells that were left in 10% fetal calf 
serum showed no difference in apoptosis (as determined by TUNEL positivity) between 
the genotypes (Figure 44a).  However, Pak1
-/-
 cells have small but significant increases in 
apoptosis compared to wild type when exposed to both PDGF-BB and TGF-β (Figure 44 
c and d).  This finding is in contrast to the results of Figure 16, which show that mast cell 
survival in response to SCF is not affected by loss of Pak1.  Taken together, these studies 
demonstrate that Pak1 anti-apoptotic effects are cell type and stimulus dependent. 
 
Loss of Pak1 inhibits fibroblast recruitment in vivo 
 
 In order to determine whether Pak1 regulates the migration of fibroblasts in 
response to growth factors in vivo, we performed ECM matrix invasion assays with wild 
type and Pak1
-/-
 mice.  Our lab has previously established that implantation of Cultrex  
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Figure 44- Pak1
-/-
 fibroblasts have decreased survival after PDGF-BB and TGF-β 
exposure.  Confluent monolayers of fibroblasts were starved for 24 hour prior to 
stimulation with 50ng/mL of PDGF-BB or 2ng/mL of TGF-β in media lacking serum.  
After 72 hours, survival was assessed by TUNEL assay according to the manufacturers 
instructions.  Values represent the mean of 6 independent experiments performed in 
triplicate and the error bars represent the standard error of the mean.  * indicates p<0.05 
compared to WT using Student’s unpaired T test. 
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basement membrane extract with PDGF-BB or TGF-β into the groin of mice induces 
fibroblast invasion from the surrounding tissue 
71
.  Seven days after Cultrex 
implantation, the plugs were removed, sectioned, and stained with hematoxylin and eosin 
(H&E) to visualize the extent of fibroblast migration.  Figure 45a displays the results 
taken from mice implanted with PDGF-BB or vehicle, showing a significant reduction in 
fibroblast recruitment in Pak1
-/-
 mice.  Representative sections that display the invading 
fibroblasts are also shown (Figure 45b-d).  In parallel experiments using plugs containing 
TGF-β, we found similar results, with a significant decrease in invading fibroblasts from 
Pak1
-/-
 mice (Figure 46a).  The amount of fibroblast infiltration can be observed in the 
representative plug sections shown in Figure 46b-d. 
 
Genetic disruption of Pak1 reduces the severity of bleomycin induced lung fibrosis 
 
 Harrison and Lezo have described an in vivo experimental murine model to 
stimulate pathologic fibrosis in lungs using bleomycin sulfate delivered from 
subcutaneously implanted micro-osmotic pumps 
172
.  Bleomycin induces lung fibrosis by 
activating both the TGF-β 189-191 as well as PDGF-BB 192-194  pathways to stimulate 
fibroblast proliferation and collagen deposition.  Inhibition of the PDGF-BB and TGF-β 
pathways via imatinib prevents bleomycin induced lung fibrosis in mice 
193
. 
 Based on these previous reports and on our in vitro findings implicating Pak1 as 
an important downstream mediator of PDGF-BB and TGF-β signals in fibroblasts, we 
used bleomycin to induce lung fibrosis in wild type and Pak1
-/-
 mice.  After 28 days of 
bleomycin or PBS exposure, lungs were harvested and either fixed for histological 
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sections or used for collagen content assays.  Figure 47a-d displays representative 
hematoxylin and eosin (H&E) stained slides taken from each genotype, revealing that 
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Figure 45- Pak1
-/-
 mice have decreased PDGF-BB mediated fibroblast invasion into 
Cultrexplugs.  A) Quantitative scoring of fibroblast invasion into Cultrexplugs 
containing PBS or 200ng/mL of PDGF-BB.  Values represent the mean of five individual 
sections from 4 mice per genotype and error bars represent the standard error of the 
mean.  * indicates p<0.05 compared to WT using Student’s unpaired T test.  Also shown 
(B-E) are representative hematoxylin and eosin (H&E) stained sections from Cultrex 
plugs containing PDGF-BB or PBS. 
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Figure 46- Pak1
-/-
 mice have decreased TGF-β mediated fibroblast invasion into 
Cultrexplugs.  A) Quantitative scoring of fibroblast invasion into Cultrexplugs 
containing PBS or 10ng/mL of TGF-β.  Values represent the mean of five individual 
sections from 4 mice per genotype and error bars represent the standard error of the 
mean.  * indicates p<0.05 compared to WT using Student’s unpaired T test.  Also shown 
(B-E) are representative hematoxylin and eosin (H&E) stained sections from Cultrex 
plugs containing TGF-β. 
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exposure to bleomycin induces dramatic fibrosis compared to PBS treated animals.   
Using a quantitative measurement of lung fibrosis developed by Ashcroft, we 
determined that Pak1
-/-
 mice had a modest (~20%), but significant (p<.0001) reduction in 
fibrosis severity compared to wild type animals (Figure 47e).  Correspondingly, using the 
Sircol assay system, we found that lungs from Pak1
-/-
 mice had a significant decrease in 
collagen content (Figure 47f), similar in degree to the change in fibrosis severity.  
Collectively, the results of Figure 47 indicate a role for Pak1 in the pathophysiology of 
bleomycin mediated lung fibrosis disease model.   
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Figure 47- Loss of Pak1 reduces bleomycin induced lung fibrosis.         
A-D) Representative hematoxylin and eosin (H&E) stained sections from lungs treated 
with either PBS or 125mg/kg/day of bleomycin sulfate for 28 days.  E) Extent of lung 
fibrosis as measured by the Ashcroft scoring system.  Fields from 8 mice per genotype 
that received either PBS or bleomycin sulfate were scored in a blinded fashion by 4 
independent researchers.  Values represent the mean score of 8 animals per condition and 
error bars represent the standard error of the mean.  * indicates p<0.05 compared to WT 
using Student’s unpaired T test.  F) After 28 days of drug exposure, lungs were removed, 
minced and collagen extracted with pepsin and acetic acid.  The amount of collagen 
present in each lung was assessed by Sircol dye assay.  Values represent the mean 
amount of collagen from lungs of 4 animals per condition performed in triplicate and 
error bars represent the standard error of the mean.  * indicates p<0.05 compared to WT 
using Student’s unpaired T test.    
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DISCUSSION 
 
In the history of neurofibromatosis type I, identification of the NF1 gene and the 
GTPase activating ability of its gene product neurofibromin 
24
 provided the keystone for 
future research into the molecular alterations responsible for the pathophysiology of this 
disease.  Based on the autosomal dominant mode of disease inheritance and the genetic 
background of tissue samples taken from patient tumors 
195
, neurofibromin has been 
commonly classified as a tumor suppressor protein.  However, work from our lab 
59,62,75
 
and others 
30,196,197
 has demonstrated that in mouse models, single copy of loss of Nf1 
leads to tumor promoting gains-in-function, in opposition to Knudson’s “two-hit” 
hypothesis 
198
.  Clinical observations from NF1 patients such as patient-to-patient 
variability in tumor number and the overall low risk of malignant transformation in 
neurofibromas support these findings of gene dosage effects.  Therefore, it is critical for 
researchers in the neurofibromatosis field to uncover the molecular nature of Nf1 
haploinsufficient phenotypes in order to completely under the disease’s progression. 
Thus, a primary objective of this thesis was to examine whether a candidate 
protein, Pak1, functioned in regulating intracellular signal transduction in NF1 relevant 
pathways and if so, whether Pak1 played a role in neurofibroma tumorigenesis.  To this 
end, a genetically engineered Pak1 knockout mouse was employed in various  
intercrosses to assess molecular, cellular, and disease phenotypes.  Loss of Pak1 
corrected multiple Nf1 haploinsufficient gain-in-function phenotypes in mast cells and 
Pak1 was demonstrated to be an important regulator of fibroblast function in response to 
two significant growth factors.  However, using genetic intercrosses as well as 
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hematopoietic cell transplantaion in an in vivo animal model that closely recapitulates 
human disease, we established that Pak1 loss is insufficient for prevention of 
neurofibroma formation. 
 
Role of Pak1 in regulating c-kit mediated Nf1
+/-
 mast cell function 
 
Mast cells carry out their functions by migrating toward signals emanating from 
local microenvironments, followed by local proliferation, and subsequently releasing 
inflammatory mediators (including proteases).  The NF1 disease model has well known 
associations between Ras related gains-in-function in mast cells and the pathologic 
complications this disorder 
59,63,199,200
.  These cellular phenotypes and increased Ras 
activity have also been observed in NF1 patient samples (S. Chen, F.C. Yang, D.W. 
Clapp, unpublished results).  
 Bone marrow mononuclear cells from Pak1
-/-
 animals develop in vitro into mature 
mast cells normally, as measured by the expression of c-kit and FcεRI surface markers 
(Figure 6).  Additionally, haploinsufficiency at Nf1 also did not affect c-kit or FcεRI 
expression levels.  Therefore the results shown in experiments utilizing mast cells were 
not the consequence of alterations in the number of ligand binding sites for SCF and 
instead due to changes in intracellular signaling.  
 Here we use pharmacologic, genetic, and biochemical approaches to demonstrate 
that the hyperproliferation of Nf1
+/-
 mast cells in response to SCF is the result of Pak1 
signaling to the MEK/Erk pathway.  Although multiple studies link Pak1 to MAPK 
signaling in overexpression systems 
131-133,160,201,202
, in this report we establish for the first 
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time in primary cells using a knockout model that Pak1 loss leads to decreased activation 
of MEK and Erk.  Importantly, subcutaneous insertion of microosmotic pumps 
continuously releasing SCF in Nf1
+/-
;Pak1
-/-
 mice corrected the increased accumulation 
of mast cells in the dermis seen in Nf1
+/-
 mice to wild type levels, correlating our in vivo 
results in a physiologically relevant system (Figure 17a) the mechanisms identified in 
vitro (Figure 7). 
Furthermore, we also demonstrate that the increased release of preformed 
mediators associated with Nf1 haploinsufficiency seen in vitro is corrected when Pak1 is 
genetically disrupted.  Interestingly, Pak1
-/-
 mast cells do not have significant decreases 
in degranulation compared to wild type cells in response to SCF and IgE stimulation 
combined (Figure 14), but do have impaired degranulation in response to IgE stimulation 
alone (Figure 15).  SCF stimulation could preferentially activate the Mek/Erk pathway, 
which we show to independent of Pak1 with regards to degranulation (Figure 15), to 
compensate for the decreased IgE dependent signals (J.D. Allen, D.W. Clapp, 
unpublished results) seen in Pak1
-/-
 cells.  Importantly, the amount of mast cell 
degranulation found in Nf1
+/-
;Pak1
-/-
 mice in vivo is significantly reduced compared to 
Nf1
+/-
 mice (Figure 17b).    
Interestingly, although Nf1
+/-
 mast cells have prolonged, Akt-mediated survival in 
response to SCF stimulation 
60
, and Pak1 has been implicated as a potential anti-apoptotic 
mediator in some cell types, we found that loss of Pak1 had no significant effect on 
apoptosis or survival in mast cells (Figure 16).  A potential explanation for this finding 
lies in the fact that Pak1’s anti-apoptotic actions have been reported to be the result of 
activation of Bad-1 
143-145
.  However, recent reports indicate that phosphorylation of Bad-
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1 is not essential to hematopoietic cell survival responses resulting from PI-3K/Akt 
activation 
203
.  Therefore our findings demonstrating the inconsequential role of Pak1 
with regards to mast cell apoptosis correlate well with data disassociating Bad-1 from 
hematopoietic cell survival. 
 A basic tenet of mast cell biology is that the mast cell progenitors circulate in the 
peripheral blood after development in the bone marrow and must migrate from the 
bloodstream to peripheral tissues.  Nf1 null Schwann cells (the tumorigenic cell of the 
neurofibroma) secrete a 6-7 fold higher concentration of SCF compared to wild type cells 
62
, which stimulates a pathologic gain in migration and proliferation of Nf1
+/-
 but not WT 
mast cells in vitro.  Hyperactive Nf1
+/-
 mast cells at the site of developing tumors could 
enhance the tumor forming ability of Schwann cells by means of their described role as 
potential “inducers” of neurofibroma pathogenesis via effects on the microenvironment 
63
.  Work submitted from our group confirms this hypothesis after we observed that 
adoptive transfer of Nf1
+/-
 mast cells, but not WT mast cells, into mice that have Nf1 
conditionally deleted in the Schwann cell compartment (Krox20Cre;Nf1
flox/flox
) is 
necessary and sufficient to allow plexiform neurofibromas to develop in vivo (F.C. Yang, 
D.A. Ingram and D.W. Clapp, manuscript submitted April 2008).   
In figure 11 we demonstrate that loss of Pak1 reduces Nf1
+/-
 mast cell migration 
by ~40% in response to SCF and that this reduction is p38 dependent.  Additionally, we 
present experimental evidence that SCF mediated increases in the F-actin cytoskeleton in 
Nf1
+/-
 BMMCs are dependent on a Pak1-p38 pathway.  Pak1
-/-
 mast cells also have a 
significant decrease in mast cell migration compared to wild type cells, but to a lesser 
degree than seen between Nf1
+/-
 and Nf1
+/-
;Pak1
-/-
 cells.  This result is similar to the 
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characteristics of p85α-/- and Rac2-/- mast cells, as they are only modestly impaired in 
their SCF mediated migration but cause large decreases in haptotaxis in the context of 
Nf1 heterozygosity 
60
.  These findings indicate that the PI-3K/Rac2/Pak1 signaling axis, 
and by extension p38, are preferentially activated to stimulate the actin cytoskeleton and 
cell migration in the context of hyperactive Ras, and that under conditions of normal 
neurofibromin activity, other accessory pathways are also used to coordinate cell 
movement.   
 In Nf1
+/-
 BMMCs, after stimulation by SCF, Ras becomes hyperactivated due to 
the lack of neurofibromin GAP activity.  This leads to increased PI-3K/Rac activation 
59,61,204
, and subsequent increases in Pak1 activity 
60
.  Hyperactivated Pak1 transmits 
mitogenic signals through selective activation of MEK and Erk and migratory signals 
through selective activation of p38 and the actin cytoskeleton.  Therefore we propose that 
Pak1 acts as a significant “hub” of c-kit mediated hyperactive Ras signaling and that 
disruption of Pak1 can reduce the pathologic increases in proliferation and migration in 
Nf1 haploinsufficient BMMCs.  
 
Pak1 and plexiform neurofibroma formation 
 
 Greater than 25% of NF1 patients have plexiform neurofibromas surrounding 
spinal nerve roots 
15
, which can cause significant morbidity and premature death 
12
.  
These tumors present major challenges to surgical treatment and no effective medical 
therapies for these tumors are available 
63
.  Further, plexiform neurofibromas have a 
propensity to transform into malignant peripheral nerve sheath tumors.  Lack of existing 
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medical therapies has encouraged investigations into the cellular interactions in the 
neurofibroma microenvironment and molecular pathways regulating them in an attempt 
to identify potential pharmacologic targets for clinical use.  Emerging evidence 
designating the mast cell as a key moderator of the pathophysiology at the site of 
neurofibroma development provides an attractive target for pharmacologic interventions. 
If molecular therapeutics designed for correcting hyperactive pathways in Nf1
+/-
 
mast cells is developed, plexiform neurofibroma formation may be delayed or even 
prevented.  For example, in recently submitted studies using the Krox20Cre;Nf1
flox/-
 
murine tumor model, we have effectively used the small molecule imatinib (which 
inhibits c-kit and other RTKs) to reduce plexiform neurofibroma mass and significantly 
extend survival 
64
.  Currently, we are using this agent in a phase II clinical trial in 
pediatric NF1 patients with plexiform neurofibromas.  Therefore, based on the in vitro 
data that implicated Pak1 as an important signaling molecule in disease related mast cell 
functions, we were eager to investigate whether loss of Pak1 would alter tumorigenesis 
using the Krox20Cre mouse model of NF1.   
 However, using both an adoptive transfer and genetic intercross approach, we 
were not able to prevent neurofibroma formation by targeted disruption of Pak1.  This 
could be due to the influence of many factors.  The findings described above that show 
corrections in gains of function in Nf1
+/-
;Pak1
-/-
 mast cells were generated from 
experiments that used soluble SCF as the stimulus.  However, in the actual tumor 
microenvironment, in addition to the soluble form, membrane bound forms of SCF exist, 
which has been described as a more potent activator of c-kit responses 
205
.  In 
neurofibromatosis type 1 in general, and plexiform neurofibroma pathophysiology 
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specifically, the relative contribution of membrane bound SCF vis-à-vis soluble SCF is 
unknown.  
The Sl
d
 mutation deletes the transmembrane and cytoplasmic domains of SCF, 
and Sl/Sl
d
 mice produce soluble but not membrane bound SCF 
45,206,207
.  Sl/Sl
d
 mice have 
macrocytic anemia and melanocyte deficits, and importantly, markedly reduced tissue 
mast cells.  Since soluble and membrane bound SCF have similar affinity for c-kit 
206
, the 
reduced mast cell numbers found in Sl/Sl
d
 mice imply that membrane bound SCF 
activates molecular signals downstream of c-kit that are essential for mast cell 
development and growth and are different than those activated by soluble SCF.  The idea 
that soluble SCF cannot fully compensate for membrane bound SCF has been shown for 
other processes such as spermatogenesis 
208
, erythropoiesis 
209
, and in vivo melanocyte 
survival 
210
 as well.  Therefore, it is possible that membrane bound SCF at the site of 
developing neurofibromas might stimulate c-Kit to activate non-Pak1 dependent 
pathways to trigger mast cell tumor inducing phenotypes in Krox20Cre;Nf1
flox/flox
 or 
Krox20Cre;Nf1
flox/-
 mice that were reconstituted with Nf1
+/-
;Pak1
-/-
 bone marrow.    
 One notable finding from the adoptive transfer experiments was that although 
both Krox20Cre;Nf1
flox/flox
 and Krox20Cre;Nf1
flox/- 
mice reconstituted with Nf1
+/-
;Pak1
-/-
 
bone marrow developed tumors, only Krox20Cre;Nf1
flox/flox
 recipients of Nf1
+/-
;Pak1
-/-
 
bone marrow showed a decrease in mast cell numbers in the tumor compared to 
recipients of Nf1
+/- 
bone marrow (Figure 22b).  Krox20Cre;Nf1
flox/- 
mice had similar 
numbers of invaded mast cells, regardless of marrow genotype (Figure 26b).  One 
conclusion that could be drawn from this finding is that haploinsufficiency of the non-
mast cell lineages of the tumor microenvironment produces more mast cell activating 
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factors compared to a wild type background.  Given that fibroblasts are obligate 
producers of membrane bound SCF 
211,212
, and that Nf1
+/-
 fibroblasts activate Nf1
+/-
 mast 
cells more intensely than wild type fibroblasts 
71
; the findings of Figure 22b and 26b may 
be explained by increased production of membrane bound SCF in fibroblasts of 
Krox20Cre;Nf1
flox/- 
mice, stimulating Nf1
+/-
;Pak1
-/-
 mast cells to proliferate and release 
their granules in a Pak1 independent fashion.  
 Another explanation for the results of the adoptive transfer neurofibroma 
experiments may lie in the unknown role of Pak2 in Nf1
+/-
 cells.  Pak2 carries out critical 
functions in cells, as homozygous disruption of the gene is embryonically lethal at a very 
early stage, and attempts to make a conditionally disrupted Pak2 knockout mouse have 
been unsuccessful at generating Pak2
flox/flox
 progeny so far (data not shown).  Pak2 shares 
high sequence homology with Pak1 (~77%) 
103
, and is highly expressed in mast cells 
(data not shown).  It is possible that after adoptive transfer of Nf1
+/-
;Pak1
-/-
 bone marrow, 
Pak2 expression or Pak2 kinase activity is increased to compensate for the loss of Pak1.  
An analogous result was found in murine MPD studies, where after adoptive transfer of 
Nf1
-/-
;Rac2
-/-
 bone marrow, the levels of Rac1-GTP increased steadily in vivo and 
leukemias developed in these mice (D.W. Clapp, unpublished data).  The relative, non-
redundant contributions of Pak1 and Pak2 to cellular functions are still unclear for all cell 
types, and will need to be examined carefully in order to determine if the Pak kinases are 
important to neurofibroma pathogenesis. 
 Other reports indicated that overexpression of dominant negative Pak1 in Nf1
-/-
 
Schwann cell lines prevented malignant transformation in vitro, leading us to hypothesize 
that mice with genetic disruption of Pak1 in tumorigenic, Nf1 null Schwann cells would 
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disrupt neurofibroma formation 
161
.  Nonetheless, the results of the genetic intercross of 
Pak1
-/-
 mice with Krox20Cre;Nf1
flox/- 
also indicated that Pak1 loss in each lineage of the 
neurofibroma was inadequate for preventing tumor development.  In addition, 
preliminary work in our laboratory using Schwann cells cultured from murine dorsal root 
ganglia has shown that Nf1
-/-
;Pak1
-/-
 Schwann cells have increased invasion and 
proliferation compared to both wild type and Nf1
-/-
 cells, in opposition to the findings of 
Tang et al. (F.C. Yang and D.W. Clapp, unpublished results).  Further investigations of 
Pak1 and its effects on Schwann cell functions are warranted, as these early findings hint 
toward a fundamentally different role for Pak1 in regulating Ras signals in the 
tumorigenic lineage in comparison to the cells of the microenvironment.    
As discussed above, the non-hematopoietic portion of the tumor 
microenvironment provides mast cell growth promoting factors.  Since 
Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice have similar numbers of mast cells within plexiform 
neurofibromas as Krox20Cre;Nf1
flox/-
 mice, it appears that the signaling pathways that 
control the production of these factors are intact in Krox20Cre;Nf1
flox/-
;Pak1
-/-
 mice to 
fully induce mast cell activation and therefore do not involve Pak1. 
As a whole, the experiments utilizing the Krox20Cre;Nf1
flox
 model clearly 
indicate that loss of Pak1 alone cannot prevent the formation of plexiform neurofibromas.  
Although loss of Pak1 clearly affects Nf1
+/-
 mast cell responses to SCF in vitro, we show 
that the rather specific conditions of those experiments are not duplicated in the complex 
milieu of differing cellular lineages and various growth factors found in the regions 
surrounding Nf1 null Schwann cells where neurofibromas originate.  Consequently, 
attempts at using recently published small molecule inhibitors of Pak1 
213
 as a single 
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agent to treat Krox20Cre;Nf1
flox/-
 mice with tumors as we have done with imatinib would 
not be recommended.  It is more plausible that successful pharmacologic approaches to 
the treatment of this disease will have to target multiple signaling molecules 
simultaneously, as the inhibition of a single component of a pathway can likely be 
compensated for by other molecules activated by one of the other cytokines present in the 
tumor.  Indeed, part of imatinib’s success at ameliorating neurofibroma progression is 
due to the fact that it inhibits RTKs other than c-Kit, such as c-Abl and PDGFR-β.  
Therefore, the future of Pak1 as a pharmacologic target in the therapy of 
neurofibromatosis type I may be relegated to that as an adjuvant therapy as part of a 
cocktail of rationally designed small molecules. 
 
The role of Pak1 in PDGF-BB and TGF-β mediated signaling in fibroblasts 
 
 Under normal conditions, fibroblasts provide structural integrity and synthesize 
growth factors and extracellular matrix in nearly every tissue system.  In addition, 
fibroblasts are intimately linked with numerous pathological conditions, including 
arthritis 
214
, asthma 
215
, and neoplasia 
216
, including plexiform neurofibromas 
67,68,71
.  
Invading fibroblasts carry out crucial tasks in cancer progression by altering the local 
extracellular matrix and by providing mitogenic signals to neoplastic cells 
217-219
.  The 
involvement of Pak1 in fibroblasts has been investigated in numerous publications using 
transformed fibroblast cell lines and overexpression systems 
101
.  Here, we present for the 
first time, evidence in a genetic knockout system using primary cells outlining an 
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important role for Pak1 in mediating PDGF-BB and TGF-β mediated responses in vitro 
and in vivo.  
Our results show that Pak1 activity is critical for the coordinated activation of the 
cytoskeleton necessary for fibroblast migration.  In cells stimulated with either PDGF-BB 
or TGF-β, Pak1-/- cells had decreased levels of activated filamin A (Figures 36 and 40), 
disruptions in F-actin organization (Figures 38h and 42h), and reduced wound healing 
responses in vitro (Figures 35 and 39).  Additionally, using an animal model assay system 
known to induce fibroblast invasion, we demonstrate that the infiltration of fibroblasts in 
vivo is significantly reduced in Pak1
-/-
 mice (Figure 45a and 46a).  Fibroblast migration 
and invasion into the provisional matrix of the fibrin clot is an initiating event of wound 
healing that precedes reproduction and contraction of the extracellular matrix.  This 
invasion step has been linked to PDGF-BB and TGF-β release by activated platelets at 
the site of the wound 
220
.  Our results indicate that Pak1 activation mediates the molecular 
responses necessary for this important physiologic process. 
Further experiments with Pak1
-/-
 fibroblasts revealed the involvement of Pak1 in 
multiple cellular functions.  We identified modest but significant increases in apoptosis 
for Pak1
-/-
 cells stimulated with PDGF-BB or TGF-β (Figure 44 c and d).  This finding is 
in contrast to the results of Figure 16, which show that mast cell survival in response to 
SCF is not affected by loss of Pak1.  Taken together, these studies demonstrate that Pak1 
anti-apoptotic effects are cell type and stimulus dependent.  Interestingly, Pak1
-/-
 
fibroblasts showed selective functional deficits depending on whether PDGF-BB or TGF-
β was used as the stimulus.  Loss of Pak1 resulted in reduced Erk activation and 
decreased proliferation in fibroblasts stimulated with PDGF-BB (Figure 31 and 32), but 
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not cells stimulated with TGF-β (Figure 32 and 33).  Other reports have utilized RNAi 
approaches to identify Pak2 as an important non-Smad pathway effector of TGF-β 
mitogenic signaling in fibroblasts 
221
.  Our findings indicate that this growth promoting 
function in response to TGF-β is specific to Pak2.  Furthermore, we find that Pak1 null 
cells have reduced collagen production in response to TGF-β stimulation, but not PDGF-
BB (Figure 43).  While both growth factors are able stimulate collagen production, Pak1 
involvement seems to be unique to TGF-β stimulation. 
Idiopathic pulmonary fibrosis (IPF) is a disease that kills 40,000 patients per year 
and is associated with progressive dyspnea, decreased pulmonary function, and 
radiographically identifiable pulmonary infiltrates 
222
. Based upon the supposed 
inflammatory etiology of the disease, IPF was traditionally treated with systemic 
corticosteroids.  However, clinical studies have revealed that corticosteroid treatments are 
ineffective and do not improve survival 
223,224
.  Currently, IPF is believed to be the result 
of overactive fibroblast activation in response to fibrogenic factors released by alveolar 
epithelial cells following repeated pulmonary microinjury 
225
.  Two of the most 
prominently increased cytokines in the lungs of IPF patients include PDGF-BB and TGF-
β 225.  Using an established animal model of bleomycin induced lung fibrosis 172, we 
found that Pak1
-/-
 mice developed a significantly less severe fibrosis and had decreased 
amounts of newly synthesized collagen after exposure to bleomycin (Figure 47e and f).  
However, the magnitude of difference of fibrosis severity between wild type and Pak1
-/-
 
mice was not dramatic (~20%), despite the high amount of statistical significance  
(p<0.0001).  This could be due to the fact that following exposure to bleomycin, 
fibroblasts in the lung proliferate in response to PDGF-BB and TGF-β 226.  However, our 
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in vitro data indicates that Pak1
-/-
 fibroblasts are deficient in only PDGF-BB mediated 
proliferation.  TGF-β mediated mitogenic responses are intact in these animals and this 
could account for the only modest improvement in fibrosis in Pak1
-/-
 mice.   
In summary, these studies recognize a function for Pak1 in mediating PDGF-BB 
and TGF-β signaling in fibroblasts.  In addition, we demonstrate that Pak1 activates of 
the actin cytoskeleton leading to cell migration and invasion, an early and critical process 
of the wound healing response.  Finally, we show that loss of Pak1 improves the lung 
pathology in an animal model of a serious human disease. 
 
Conclusions and future directions 
 
 In the studies described here,  we identify a role for Pak1 in coordinating 
molecular signaling in multiple cell types.  We report for the first time in a primary cell 
model that Pak1 activates the MAPK signaling pathway.  We establish that Pak1 
regulates the characteristic hyperactivation of the MAPK pathway and several associated 
gain-in-function phenotypes found in Nf1
+/-
 mast cells stimulated with SCF, including 
proliferation, migration, and degranulation.  Surprisingly, we found that the corrections in 
Nf1 haploinsufficient mast cell functions caused by loss of Pak1 in vitro did not affect the 
development of plexiform neurofibromas in Krox20Cre;Nf1
flox/-
 mice.  The unexpected 
results of the plexiform neurofibroma studies underscore the unique insight provided by 
animal models into the complex cell-to-cell interactions underlying tumorigenesis in a 
manner that in vitro studies cannot replicate.  Further experiments utilizing the 
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Krox20Cre;Nf1
flox/-
 mouse model are critical for validating the proposed biochemical 
schema generated from our cellular data.   
One set of studies with particular relevance to the role of Pak1 and neurofibroma 
formation involves the adoptive transfer of Nf1
+/-
;Rac1
-/-
 bone marrow into 
Krox20Cre;Nf1
flox/-
 mice.  If these mice have interrupted tumor formation, it would 
provide more evidence that Rac-GTPase signaling in hematopoietic cells during tumor 
formation employs other downstream mediators in addition to Pak1, and that signaling 
cues from the microenvironment preferentially activate these alternate pathways.  In 
addition, the successful development of a Pak2 conditional knockout mouse would prove 
very useful for the study of neurofibroma pathophysiology.  The mast cell assays 
described here be repeated with Nf1
+/-
;Pak2
flox/flox
 mice, and compared to the results 
described here using Pak1
-/-
 cells to determine if non-redundant functions of the Pak 
isoforms exist.  In particular, it would be of interest to see if Pak2 null mast cells had 
changes in survival or maturation, two functions where Pak1 appears to be non-essential.  
The generation of Nf1
+/-
;Pak1
-/-
;Pak2
flox/flox
 mutant bone marrow would be particularly 
valuable for adoptive transfer into Krox20Cre;Nf1
flox/-
 mice for tumor studies similar to 
those performed here.  We hypothesize that transplantation of Nf1 haploinsufficient 
hematopoietic cells lacking both Pak1 and Pak2 will delay neurofibroma formation.  An 
additional line of experimentation to follow up on these studies involves the role of 
membrane bound SCF to neurofibroma formation.  Intercrossing the Krox20Cre;Nf1
flox/-
 
mouse with Sl/Sl
d
 mouse and following plexiform neurofibroma formation in the progeny 
would provide an easily interpretable method for assessing the contribution of the 
membrane bound form of SCF to tumor pathology.   
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In addition, this report demonstrates that Pak1 is necessary for activating various 
fibroblast functions in response to PDGF-BB and TGF-β.  These fibroblast studies point 
out a potential responsibility for Pak1 in regulating physiologic functions such as wound 
healing.  Keloids are pathologic scars formed by overactive wound healing responses.  
Experiments utilizing recently developed Pak1 inhibitors 
213
 could be used in murine 
models of keloid development 
227
, to investigate whether the putative role for Pak1 in 
wound healing outlined in this work is involved in this disease process.  Lastly, we also 
establish a role for Pak1 in a significant respiratory disease, idiopathic pulmonary 
fibrosis.  Although the decreases in bleomycin induced lung fibrosis are not drastic in 
Pak1
-/-
 mice, it is unknown what a 20% change in fibrosis severity and collagen content 
means in relation to overall pulmonary function.  Therefore, it would be of interest to 
compare airway morphometry, resistance, and ventilation/perfusion ratios of lungs 
harvested from bleomycin treated wild type and Pak1
-/-
 mice.  
These studies demonstrate that Pak1 is a key regulator of various cellular 
functions in both mast cells and fibroblasts by activating multiple pathways, including 
Ras/Raf/Mek/Erk, p38 MAPK, and actin regulating proteins, in the context of both 
normal and hyperactivated Ras.  We provide novel data that identifies Pak1 as a potential 
target for therapeutic interventions in fibrotic diseases.  Our findings have enhanced the 
understanding of the molecular underpinnings of neurofibromatosis type 1, providing 
knowledge into the pathogenesis of this common and debilitating disease.  Due to its 
critical location at the intersection of numerous signaling networks responsible for 
important biological outcomes, further investigation into Pak1 and related isoforms holds 
great potential for future researchers and clinicians.  
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